2P3YP3Yfalse--12-31Q1202000012276541070000095000000.720.720.010.012000000002000000003536726435367264250000000.05000000000.048750.0370.067528000000000P4Y14816111475196 0001227654 2020-01-01 2020-03-31 0001227654 2020-05-01 0001227654 2019-12-31 0001227654 2020-03-31 0001227654 2019-01-01 2019-03-31 0001227654 us-gaap:ProductMember 2019-01-01 2019-03-31 0001227654 us-gaap:ProductMember 2020-01-01 2020-03-31 0001227654 us-gaap:ShippingAndHandlingMember 2019-01-01 2019-03-31 0001227654 us-gaap:ShippingAndHandlingMember 2020-01-01 2020-03-31 0001227654 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0001227654 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001227654 2018-12-31 0001227654 us-gaap:CommonStockMember 2018-12-31 0001227654 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001227654 us-gaap:TreasuryStockMember 2018-12-31 0001227654 2019-03-31 0001227654 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001227654 us-gaap:RetainedEarningsMember 2019-03-31 0001227654 us-gaap:AccountingStandardsUpdate201602Member us-gaap:RetainedEarningsMember 2019-01-01 0001227654 us-gaap:RetainedEarningsMember 2018-12-31 0001227654 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001227654 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001227654 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001227654 us-gaap:TreasuryStockMember 2019-03-31 0001227654 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001227654 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001227654 us-gaap:CommonStockMember 2019-03-31 0001227654 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001227654 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001227654 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001227654 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001227654 us-gaap:CommonStockMember 2019-12-31 0001227654 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001227654 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001227654 us-gaap:CommonStockMember 2020-03-31 0001227654 us-gaap:TreasuryStockMember 2020-03-31 0001227654 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0001227654 us-gaap:TreasuryStockMember 2019-12-31 0001227654 us-gaap:RetainedEarningsMember 2020-03-31 0001227654 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001227654 us-gaap:RetainedEarningsMember 2019-12-31 0001227654 us-gaap:AccountingStandardsUpdate201613Member 2020-01-01 0001227654 us-gaap:AccountingStandardsUpdate201613Member 2020-03-31 0001227654 us-gaap:MachineryAndEquipmentMember 2020-03-31 0001227654 us-gaap:ConstructionInProgressMember 2019-12-31 0001227654 us-gaap:MiningPropertiesAndMineralRightsMember 2020-03-31 0001227654 us-gaap:LandBuildingsAndImprovementsMember 2020-03-31 0001227654 us-gaap:ConstructionInProgressMember 2020-03-31 0001227654 us-gaap:LandBuildingsAndImprovementsMember 2019-12-31 0001227654 us-gaap:FurnitureAndFixturesMember 2020-03-31 0001227654 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001227654 us-gaap:MachineryAndEquipmentMember 2019-12-31 0001227654 us-gaap:MiningPropertiesAndMineralRightsMember 2019-12-31 0001227654 us-gaap:CorporateNonSegmentMember 2020-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:PlantNutritionSouthAmericaMember 2020-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:PlantNutritionNorthAmericaMember 2020-03-31 0001227654 us-gaap:CorporateNonSegmentMember 2019-12-31 0001227654 us-gaap:OperatingSegmentsMember cmp:PlantNutritionSouthAmericaMember 2019-12-31 0001227654 us-gaap:OperatingSegmentsMember cmp:PlantNutritionNorthAmericaMember 2019-12-31 0001227654 2018-01-01 2018-12-31 0001227654 srt:ScenarioForecastMember us-gaap:DomesticCountryMember cmp:TaxYear2007Through2016Member 2020-12-31 0001227654 us-gaap:ForeignCountryMember us-gaap:CanadaRevenueAgencyMember 2020-03-31 0001227654 us-gaap:ForeignCountryMember cmp:NOLCarryforwardsExpireBeginningIn2033Member 2019-12-31 0001227654 us-gaap:ForeignCountryMember cmp:NOLCarryforwardsExpireBeginningIn2033Member 2020-03-31 0001227654 us-gaap:ForeignCountryMember cmp:TaxYear2013Through2021Member 2019-04-01 2019-06-30 0001227654 us-gaap:ForeignCountryMember us-gaap:CanadaRevenueAgencyMember cmp:TaxYear2007Through2016Member 2017-01-01 2017-12-31 0001227654 us-gaap:ForeignCountryMember cmp:NOLCarryforwardsExpireBeginningIn2027Member 2019-12-31 0001227654 us-gaap:DomesticCountryMember cmp:TaxYear2007Through2016Member 2019-01-01 2019-12-31 0001227654 us-gaap:ForeignCountryMember cmp:TaxYear2007Through2016Member 2018-01-01 2018-12-31 0001227654 cmp:TaxYear2013Through2021Member 2020-01-01 2020-03-31 0001227654 srt:ScenarioForecastMember us-gaap:ForeignCountryMember cmp:TaxYear2013Through2021Member 2020-12-31 0001227654 cmp:TaxYear2013Through2021Member 2019-04-01 2019-06-30 0001227654 2019-01-01 2019-12-31 0001227654 us-gaap:ForeignCountryMember cmp:NOLCarryforwardsExpireBeginningIn2027Member 2020-03-31 0001227654 cmp:TaxYear2007Through2016Member 2018-01-01 2018-12-31 0001227654 us-gaap:DomesticCountryMember cmp:TaxYear2013Through2021Member 2020-01-01 2020-03-31 0001227654 us-gaap:ForeignCountryMember 2019-12-31 0001227654 2017-01-01 2017-12-31 0001227654 us-gaap:ForeignCountryMember 2020-03-31 0001227654 srt:ScenarioForecastMember us-gaap:DomesticCountryMember cmp:TaxYear2013Through2021Member 2020-12-31 0001227654 srt:MaximumMember cmp:BrazilianReaisdenominatedLoansMember cmp:CertificadoDeDepositoInterbancarioCDIMember 2020-03-31 0001227654 cmp:BrazilianReaisdenominatedLoansMember 2020-01-01 2020-03-31 0001227654 srt:MinimumMember cmp:BrazilianReaisdenominatedLoansMember cmp:CertificadoDeDepositoInterbancarioCDIMember 2020-03-31 0001227654 cmp:CertificadoDeDepositoInterbancarioCDIMember 2020-03-31 0001227654 cmp:EuroDenominatedLoansMember 2020-01-01 2020-03-31 0001227654 cmp:BrazilianReaisdenominatedLoansMember 2020-03-31 0001227654 us-gaap:RevolvingCreditFacilityMember cmp:RevolvingCreditFacilityDueJanuary2025Member 2020-03-31 0001227654 cmp:BancoRabobankDueJuly2021Member 2019-12-31 0001227654 cmp:TermLoanDueJanuary2025Member 2019-12-31 0001227654 cmp:SeniorNotesDecember2027Member 2020-03-31 0001227654 us-gaap:RevolvingCreditFacilityMember cmp:RevolvingCreditFacilityDueJanuary2025Member 2019-12-31 0001227654 cmp:TermLoanDueJanuary2025Member 2020-03-31 0001227654 cmp:BancoRabobankLoanDueNovember2021Member 2020-03-31 0001227654 cmp:FinanciadoraDeEstudosEProjetosLoanDueNovember2023Member 2019-12-31 0001227654 cmp:BancoItauLoanDueFebruary2021Member 2020-03-31 0001227654 cmp:BancoSantanderDueDecember2021Member 2020-03-31 0001227654 cmp:BancoSantanderLoanDueSeptember2021Member 2019-12-31 0001227654 cmp:FinanciadoraDeEstudosEProjetosLoanDueNovember2023Member 2020-03-31 0001227654 cmp:BancoItauLoanDueFebruary2021Member 2019-12-31 0001227654 cmp:BancoSantanderloanDueOctober2020Member 2020-03-31 0001227654 cmp:SeniorNotesDecember2027Member 2019-12-31 0001227654 cmp:A3.7BancoItaLoanDueMarch2020Member 2020-03-31 0001227654 cmp:BancoDoBrasildueSeptember2021Member 2019-12-31 0001227654 cmp:A4.875SeniorNotesJuly2024Member us-gaap:SeniorNotesMember 2020-03-31 0001227654 cmp:BancoRabobankLoanDueNovember2021Member 2019-12-31 0001227654 cmp:BancoSantanderloanDueOctober2020Member 2019-12-31 0001227654 cmp:BancoSantanderLoanDueSeptember2021Member 2020-03-31 0001227654 cmp:A4.875SeniorNotesJuly2024Member us-gaap:SeniorNotesMember 2019-12-31 0001227654 cmp:BancoVotorantimFebruary2022Member 2020-03-31 0001227654 cmp:BancoSantanderDueMarch2022Member 2020-03-31 0001227654 cmp:BancoVotorantimFebruary2022Member 2019-12-31 0001227654 cmp:BancoRabobankDueJuly2021Member 2020-03-31 0001227654 cmp:A3.7BancoItaLoanDueMarch2020Member 2019-12-31 0001227654 cmp:BancoSantanderDueDecember2021Member 2019-12-31 0001227654 cmp:BancoDoBrasildueSeptember2021Member 2020-03-31 0001227654 cmp:BancoSantanderDueMarch2022Member 2019-12-31 0001227654 cmp:BrazilianTaxLitigationAndAssessmentsMember 2020-03-31 0001227654 cmp:ProduqumicaIndstriaeComrcioS.A.Member 2020-03-31 0001227654 cmp:ProduqumicaIndstriaeComrcioS.A.Member 2019-12-31 0001227654 cmp:BrazilianTaxLitigationAndAssessmentsMember 2019-12-31 0001227654 us-gaap:OperatingSegmentsMember cmp:PlantNutritionSouthAmericaMember 2020-01-01 2020-03-31 0001227654 cmp:HighwayDeicingSaltMember 2019-01-01 2019-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:PlantNutritionSouthAmericaMember 2019-01-01 2019-03-31 0001227654 us-gaap:CorporateNonSegmentMember us-gaap:ProductAndServiceOtherMember 2019-01-01 2019-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:PlantNutritionNorthAmericaMember 2019-01-01 2019-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:HighwayDeicingSaltMember cmp:SaltMember 2019-01-01 2019-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:SOPandSpecialtyPlantNutrientsMember cmp:PlantNutritionNorthAmericaMember 2019-01-01 2019-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:ConsumerIndustrialSaltMember cmp:SaltMember 2019-01-01 2019-03-31 0001227654 us-gaap:CorporateNonSegmentMember cmp:SOPandSpecialtyPlantNutrientsMember 2019-01-01 2019-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:IndustrialChemicalsMember cmp:PlantNutritionNorthAmericaMember 2019-01-01 2019-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:HighwayDeicingSaltMember cmp:PlantNutritionSouthAmericaMember 2019-01-01 2019-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:SOPandSpecialtyPlantNutrientsMember cmp:PlantNutritionSouthAmericaMember 2019-01-01 2019-03-31 0001227654 us-gaap:OperatingSegmentsMember us-gaap:ProductAndServiceOtherMember cmp:SaltMember 2019-01-01 2019-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:SOPandSpecialtyPlantNutrientsMember cmp:SaltMember 2019-01-01 2019-03-31 0001227654 us-gaap:CorporateNonSegmentMember cmp:ConsumerIndustrialSaltMember 2019-01-01 2019-03-31 0001227654 us-gaap:CorporateNonSegmentMember cmp:HighwayDeicingSaltMember 2019-01-01 2019-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:ConsumerIndustrialSaltMember cmp:PlantNutritionNorthAmericaMember 2019-01-01 2019-03-31 0001227654 us-gaap:OperatingSegmentsMember us-gaap:ProductAndServiceOtherMember cmp:PlantNutritionNorthAmericaMember 2019-01-01 2019-03-31 0001227654 cmp:SOPandSpecialtyPlantNutrientsMember 2019-01-01 2019-03-31 0001227654 cmp:IndustrialChemicalsMember 2019-01-01 2019-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:IndustrialChemicalsMember cmp:SaltMember 2019-01-01 2019-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:ConsumerIndustrialSaltMember cmp:PlantNutritionSouthAmericaMember 2019-01-01 2019-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:IndustrialChemicalsMember cmp:PlantNutritionSouthAmericaMember 2019-01-01 2019-03-31 0001227654 us-gaap:CorporateNonSegmentMember cmp:IndustrialChemicalsMember 2019-01-01 2019-03-31 0001227654 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-03-31 0001227654 us-gaap:OperatingSegmentsMember us-gaap:ProductAndServiceOtherMember cmp:PlantNutritionSouthAmericaMember 2019-01-01 2019-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:HighwayDeicingSaltMember cmp:PlantNutritionNorthAmericaMember 2019-01-01 2019-03-31 0001227654 cmp:ConsumerIndustrialSaltMember 2019-01-01 2019-03-31 0001227654 us-gaap:IntersegmentEliminationMember us-gaap:ProductAndServiceOtherMember 2019-01-01 2019-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:SaltMember 2019-01-01 2019-03-31 0001227654 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-03-31 0001227654 us-gaap:OperatingSegmentsMember us-gaap:ShippingAndHandlingMember cmp:PlantNutritionSouthAmericaMember 2020-01-01 2020-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:PlantNutritionNorthAmericaMember 2020-01-01 2020-03-31 0001227654 us-gaap:IntersegmentEliminationMember cmp:PlantNutritionSouthAmericaMember 2020-01-01 2020-03-31 0001227654 us-gaap:CorporateNonSegmentMember us-gaap:ShippingAndHandlingMember 2020-01-01 2020-03-31 0001227654 us-gaap:OperatingSegmentsMember us-gaap:ShippingAndHandlingMember cmp:PlantNutritionNorthAmericaMember 2020-01-01 2020-03-31 0001227654 us-gaap:OperatingSegmentsMember us-gaap:ShippingAndHandlingMember cmp:SaltMember 2020-01-01 2020-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:SaltMember 2020-01-01 2020-03-31 0001227654 us-gaap:IntersegmentEliminationMember cmp:SaltMember 2020-01-01 2020-03-31 0001227654 us-gaap:IntersegmentEliminationMember 2020-01-01 2020-03-31 0001227654 us-gaap:IntersegmentEliminationMember cmp:PlantNutritionNorthAmericaMember 2020-01-01 2020-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:SaltMember 2020-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:ConsumerIndustrialSaltMember cmp:PlantNutritionNorthAmericaMember 2020-01-01 2020-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:IndustrialChemicalsMember cmp:SaltMember 2020-01-01 2020-03-31 0001227654 us-gaap:OperatingSegmentsMember us-gaap:ProductAndServiceOtherMember cmp:PlantNutritionSouthAmericaMember 2020-01-01 2020-03-31 0001227654 cmp:HighwayDeicingSaltMember 2020-01-01 2020-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:HighwayDeicingSaltMember cmp:PlantNutritionSouthAmericaMember 2020-01-01 2020-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:ConsumerIndustrialSaltMember cmp:SaltMember 2020-01-01 2020-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:ConsumerIndustrialSaltMember cmp:PlantNutritionSouthAmericaMember 2020-01-01 2020-03-31 0001227654 us-gaap:OperatingSegmentsMember us-gaap:ProductAndServiceOtherMember cmp:PlantNutritionNorthAmericaMember 2020-01-01 2020-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:SOPandSpecialtyPlantNutrientsMember cmp:SaltMember 2020-01-01 2020-03-31 0001227654 cmp:ConsumerIndustrialSaltMember 2020-01-01 2020-03-31 0001227654 us-gaap:CorporateNonSegmentMember cmp:IndustrialChemicalsMember 2020-01-01 2020-03-31 0001227654 us-gaap:OperatingSegmentsMember us-gaap:ProductAndServiceOtherMember cmp:SaltMember 2020-01-01 2020-03-31 0001227654 cmp:IndustrialChemicalsMember 2020-01-01 2020-03-31 0001227654 us-gaap:IntersegmentEliminationMember us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-03-31 0001227654 us-gaap:CorporateNonSegmentMember cmp:ConsumerIndustrialSaltMember 2020-01-01 2020-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:IndustrialChemicalsMember cmp:PlantNutritionSouthAmericaMember 2020-01-01 2020-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:HighwayDeicingSaltMember cmp:SaltMember 2020-01-01 2020-03-31 0001227654 us-gaap:CorporateNonSegmentMember cmp:HighwayDeicingSaltMember 2020-01-01 2020-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:SOPandSpecialtyPlantNutrientsMember cmp:PlantNutritionNorthAmericaMember 2020-01-01 2020-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:SOPandSpecialtyPlantNutrientsMember cmp:PlantNutritionSouthAmericaMember 2020-01-01 2020-03-31 0001227654 us-gaap:CorporateNonSegmentMember cmp:SOPandSpecialtyPlantNutrientsMember 2020-01-01 2020-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:IndustrialChemicalsMember cmp:PlantNutritionNorthAmericaMember 2020-01-01 2020-03-31 0001227654 us-gaap:CorporateNonSegmentMember us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:HighwayDeicingSaltMember cmp:PlantNutritionNorthAmericaMember 2020-01-01 2020-03-31 0001227654 cmp:SOPandSpecialtyPlantNutrientsMember 2020-01-01 2020-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:SaltMember 2019-03-31 0001227654 us-gaap:IntersegmentEliminationMember cmp:PlantNutritionSouthAmericaMember 2019-01-01 2019-03-31 0001227654 us-gaap:OperatingSegmentsMember us-gaap:ShippingAndHandlingMember cmp:SaltMember 2019-01-01 2019-03-31 0001227654 us-gaap:OperatingSegmentsMember us-gaap:ShippingAndHandlingMember cmp:PlantNutritionSouthAmericaMember 2019-01-01 2019-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:PlantNutritionSouthAmericaMember 2019-03-31 0001227654 us-gaap:OperatingSegmentsMember us-gaap:ShippingAndHandlingMember cmp:PlantNutritionNorthAmericaMember 2019-01-01 2019-03-31 0001227654 us-gaap:OperatingSegmentsMember cmp:PlantNutritionNorthAmericaMember 2019-03-31 0001227654 us-gaap:CorporateNonSegmentMember us-gaap:ShippingAndHandlingMember 2019-01-01 2019-03-31 0001227654 us-gaap:CorporateNonSegmentMember 2019-03-31 0001227654 us-gaap:IntersegmentEliminationMember cmp:PlantNutritionNorthAmericaMember 2019-01-01 2019-03-31 0001227654 us-gaap:IntersegmentEliminationMember cmp:SaltMember 2019-01-01 2019-03-31 0001227654 us-gaap:IntersegmentEliminationMember 2019-01-01 2019-03-31 0001227654 country:GB 2019-01-01 2019-03-31 0001227654 country:CA 2020-01-01 2020-03-31 0001227654 country:BR 2019-01-01 2019-03-31 0001227654 country:GB 2020-01-01 2020-03-31 0001227654 country:CA 2019-01-01 2019-03-31 0001227654 country:US 2019-01-01 2019-03-31 0001227654 country:BR 2020-01-01 2020-03-31 0001227654 cmp:OtherGeographicAreasMember 2019-01-01 2019-03-31 0001227654 cmp:OtherGeographicAreasMember 2020-01-01 2020-03-31 0001227654 country:US 2020-01-01 2020-03-31 0001227654 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-03-31 0001227654 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-12-31 0001227654 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-03-31 0001227654 us-gaap:AccumulatedTranslationAdjustmentMember 2019-03-31 0001227654 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0001227654 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0001227654 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-03-31 0001227654 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-03-31 0001227654 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0001227654 us-gaap:CommodityContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0001227654 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001227654 us-gaap:ProductMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-03-31 0001227654 us-gaap:ProductMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-03-31 0001227654 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0001227654 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0001227654 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-03-31 0001227654 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0001227654 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-03-31 0001227654 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001227654 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0001227654 us-gaap:CommodityContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0001227654 srt:MinimumMember cmp:ReturnOnInvestedCapitalPerformanceStockUnitsMember 2020-01-01 2020-03-31 0001227654 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0001227654 srt:MinimumMember cmp:TotalShareholderReturnPerformanceStockUnitsMember 2020-01-01 2020-03-31 0001227654 srt:MaximumMember cmp:ReturnOnInvestedCapitalPerformanceStockUnitsMember 2020-01-01 2020-03-31 0001227654 cmp:PerformanceStockUnitsPsuMember 2020-03-31 0001227654 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001227654 us-gaap:RestrictedStockUnitsRSUMember 2020-03-31 0001227654 srt:MaximumMember cmp:TotalShareholderReturnPerformanceStockUnitsMember 2020-01-01 2020-03-31 0001227654 us-gaap:EmployeeStockOptionMember 2020-03-31 0001227654 cmp:Two015IncentiveAwardPlanMember 2015-05-31 0001227654 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001227654 us-gaap:EmployeeStockOptionMember 2019-12-31 0001227654 cmp:PerformanceStockUnitsPsuMember 2020-01-01 2020-03-31 0001227654 cmp:PerformanceStockUnitsPsuMember 2019-12-31 0001227654 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0001227654 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0001227654 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-03-31 0001227654 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0001227654 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-03-31 0001227654 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-03-31 0001227654 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-03-31 0001227654 us-gaap:AccumulatedTranslationAdjustmentMember 2020-03-31 0001227654 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0001227654 cmp:TotalShareholderReturnPerformanceStockUnitsMember 2020-01-01 2020-03-31 0001227654 cmp:ReturnOnInvestedCapitalPerformanceStockUnitsMember 2020-01-01 2020-03-31 0001227654 us-gaap:CommodityContractMember 2019-12-31 0001227654 us-gaap:CommodityContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001227654 us-gaap:CommodityContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-03-31 0001227654 us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001227654 us-gaap:CommodityContractMember 2020-03-31 0001227654 us-gaap:CommodityContractMember 2020-03-31 2020-03-31 0001227654 us-gaap:CurrencySwapMember 2020-03-31 0001227654 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2020-03-31 0001227654 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2020-01-01 2020-03-31 0001227654 us-gaap:OtherCurrentAssetsMember us-gaap:CommodityContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001227654 cmp:AccruedExpensesMember us-gaap:CommodityContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001227654 us-gaap:OtherAssetsMember us-gaap:CommodityContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001227654 us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001227654 us-gaap:OtherCurrentAssetsMember us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001227654 cmp:AccruedExpensesMember us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001227654 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CommodityContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001227654 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CommodityContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001227654 us-gaap:OtherAssetsMember us-gaap:CommodityContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001227654 us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001227654 cmp:AccruedExpensesMember us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001227654 cmp:AccruedExpensesMember us-gaap:CommodityContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001227654 us-gaap:OtherCurrentAssetsMember us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001227654 us-gaap:OtherCurrentAssetsMember us-gaap:CommodityContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001227654 us-gaap:CommodityContractMember 2019-12-31 2019-12-31 0001227654 us-gaap:CurrencySwapMember 2019-12-31 0001227654 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001227654 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001227654 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001227654 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001227654 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001227654 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001227654 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001227654 us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001227654 cmp:MutualFundInvestmentsConcentrationRiskMember us-gaap:ShortTermInvestmentsMember 2020-03-31 2020-03-31 0001227654 cmp:MutualFundInvestmentsConcentrationRiskMember cmp:BondFundsMember 2019-12-31 2019-12-31 0001227654 cmp:SeniorNotesdue2027Member 2020-03-31 0001227654 cmp:SeniorNotesDecember2027Member us-gaap:SeniorNotesMember 2020-03-31 0001227654 cmp:CreditAgreementMember 2020-03-31 0001227654 cmp:CreditAgreementMember 2019-12-31 0001227654 cmp:MutualFundInvestmentsConcentrationRiskMember cmp:CommonStockInternationalCompaniesMember 2020-03-31 2020-03-31 0001227654 cmp:MutualFundInvestmentsConcentrationRiskMember cmp:BlendedFundsMember 2020-03-31 2020-03-31 0001227654 cmp:MutualFundInvestmentsConcentrationRiskMember cmp:CommonStockInternationalCompaniesMember 2019-12-31 2019-12-31 0001227654 cmp:MutualFundInvestmentsConcentrationRiskMember cmp:BlendedFundsMember 2019-12-31 2019-12-31 0001227654 cmp:MutualFundInvestmentsConcentrationRiskMember cmp:CommonStockOfSmallToMidCapUSCompaniesMember 2019-12-31 2019-12-31 0001227654 cmp:MutualFundInvestmentsConcentrationRiskMember cmp:CommonstockLargeCapUSCompaniesMember 2019-12-31 2019-12-31 0001227654 cmp:MutualFundInvestmentsConcentrationRiskMember cmp:CommonstockLargeCapUSCompaniesMember 2020-03-31 2020-03-31 0001227654 cmp:MutualFundInvestmentsConcentrationRiskMember cmp:CommonStockOfSmallToMidCapUSCompaniesMember 2020-03-31 2020-03-31 0001227654 cmp:MutualFundInvestmentsConcentrationRiskMember cmp:BondFundsMember 2020-03-31 2020-03-31 0001227654 cmp:SeniorNotesDecember2027Member us-gaap:SeniorNotesMember 2019-12-31 0001227654 cmp:MutualFundInvestmentsConcentrationRiskMember us-gaap:ShortTermInvestmentsMember 2019-12-31 2019-12-31 0001227654 cmp:SeniorNotesdue2027Member 2019-12-31 utreg:MMBTU cmp:Business xbrli:pure cmp:counterparty iso4217:USD xbrli:shares cmp:segment cmp:loan xbrli:shares iso4217:USD
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2020
or
  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______________________ to __________________________
Commission File Number 001-31921
COMPASSLOGOA05.JPG
Compass Minerals International, Inc.
(Exact name of registrant as specified in its charter)
Delaware
36-3972986
(State or other jurisdiction of
 incorporation or organization)
(I.R.S. Employer
Identification Number)
9900 West 109th Street
Suite 100
Overland Park, KS 66210
(913) 344-9200
(Address of principal executive offices, zip code and telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Trading Symbol
 
Name of each exchange on which registered
Common stock, $0.01 par value
 
CMP
 
The New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes
No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period
that the registrant was required to submit and post such files)
Yes
No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Accelerated filer
Non-accelerated filer
Smaller reporting company
 
 
 
 
 
 
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes
No
The number of shares outstanding of the registrant’s common stock, $0.01 par value per share, as of May 1, 2020, was 33,904,602 shares.
 


Table of Contents

COMPASS MINERALS INTERNATIONAL, INC.

TABLE OF CONTENTS
 
 
Page
 
 
 
 
PART I. FINANCIAL INFORMATION
 
 
 
 
 
 
 
 
 
2
 
 
 
 
3
 
 
 
 
4
 
 
 
 
5
 
 
 
 
6
 
 
 
 
7
 
 
 
23
 
 
 
33
 
 
 
33
 
 
 
 
PART II. OTHER INFORMATION
 
 
 
 
34
 
 
 
34
 
 
 
35
 
 
 
35
 
 
 
35
 
 
 
35
 
 
 
36
 
 
 
37

1

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1.    Financial Statements
COMPASS MINERALS INTERNATIONAL, INC.
CONSOLIDATED BALANCE SHEETS
(in millions, except share data)
 
(Unaudited)
 
 
 
March 31,
2020
 
December 31,
2019
ASSETS
Current assets:
 
 
 
Cash and cash equivalents
$
109.8

 
$
34.7

Receivables, less allowance for doubtful accounts of $9.5 in 2020 and $10.7 in 2019
225.0

 
342.4

Inventories
254.2

 
311.5

Other
37.2

 
96.4

Total current assets
626.2

 
785.0

Property, plant and equipment, net
953.8

 
1,030.8

Intangible assets, net
88.6

 
103.0

Goodwill
274.7

 
343.0

Investment in equity investee
23.1

 
24.9

Other
144.4

 
156.5

Total assets
$
2,110.8

 
$
2,443.2

 
 
 
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
 
 
 
Current portion of long-term debt
$
40.1

 
$
52.1

Accounts payable
112.8

 
126.2

Accrued salaries and wages
24.7

 
34.4

Income taxes payable
2.7

 
10.4

Accrued interest
16.9

 
11.3

Accrued expenses and other current liabilities
62.1

 
61.5

Total current liabilities
259.3

 
295.9

Long-term debt, net of current portion
1,253.7

 
1,363.9

Deferred income taxes, net
81.9

 
89.9

Other noncurrent liabilities
154.4

 
163.9

Commitments and contingencies (Note 9)


 


Stockholders’ equity:
 
 
 
Common stock: $0.01 par value, 200,000,000 authorized shares; 35,367,264 issued shares
0.4

 
0.4

Additional paid-in capital
119.6

 
117.1

Treasury stock, at cost — 1,475,196 shares at March 31, 2020 and 1,481,611 shares at December 31, 2019
(3.3
)
 
(3.2
)
Retained earnings
610.1

 
607.4

Accumulated other comprehensive loss
(365.3
)
 
(192.1
)
Total stockholders’ equity
361.5

 
529.6

Total liabilities and stockholders’ equity
$
2,110.8

 
$
2,443.2


The accompanying notes are an integral part of the consolidated financial statements.


2


COMPASS MINERALS INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, in millions, except share and per share data)
 
Three Months Ended
March 31,
 
2020
 
2019
Sales
$
413.9

 
$
403.7

Shipping and handling cost
101.8

 
112.9

Product cost
224.8

 
218.2

Gross profit
87.3

 
72.6

Selling, general and administrative expenses
43.1

 
39.4

Operating earnings
44.2

 
33.2

 
 
 
 
Other expense (income):
 
 
 
Interest expense
19.0

 
16.2

Net loss in equity investee
0.1

 
0.1

(Gain) loss on foreign exchange
(14.3
)
 
5.0

Other, net
0.1

 
(0.6
)
Earnings before income taxes
39.3

 
12.5

Income tax expense
11.7

 
4.9

Net earnings
$
27.6

 
$
7.6

 
 
 
 
Basic net earnings per common share
$
0.80

 
$
0.22

Diluted net earnings per common share
$
0.80

 
$
0.22

 
 
 
 
Weighted-average common shares outstanding (in thousands):
 
 
 
Basic
33,892

 
33,874

Diluted
33,892

 
33,874


The accompanying notes are an integral part of the consolidated financial statements.


3


COMPASS MINERALS INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME
(Unaudited, in millions)
 
Three Months Ended
March 31,
 
2020
 
2019
Net earnings
$
27.6

 
$
7.6

Other comprehensive income (loss):
 
 
 
Unrealized gain from change in pension obligations, net of tax of $(0.0) in both 2020 and 2019
0.2

 
0.1

Unrealized gain on cash flow hedges, net of tax of $(0.0) in both 2020 and 2019
0.1

 
0.1

Cumulative translation adjustment
(173.5
)
 
14.5

Comprehensive (loss) income
$
(145.6
)
 
$
22.3


The accompanying notes are an integral part of the consolidated financial statements.


4


COMPASS MINERALS INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
For the three months ended March 31, 2020 and 2019
(Unaudited, in millions)
 
Common
Stock
 
Additional
Paid-In
Capital
 
Treasury
Stock
 
Retained
Earnings
 
Accumulated
Other
Comprehensive
Loss
 
Total
Balance, December 31, 2019
$
0.4

 
$
117.1

 
$
(3.2
)
 
$
607.4

 
$
(192.1
)
 
$
529.6

Comprehensive income (loss)
 
 
 
 
 
 
27.6

 
(173.2
)
 
(145.6
)
Dividends on common stock ($0.72 per share)
 
 
0.1

 
 
 
(24.9
)
 
 
 
(24.8
)
Shares issued for stock units, net of shares withheld for taxes
 
 
 
 
(0.1
)
 
 
 
 
 
(0.1
)
Stock-based compensation
 
 
2.4

 
 
 
 
 
 
 
2.4

Balance, March 31, 2020
$
0.4

 
$
119.6

 
$
(3.3
)
 
$
610.1

 
$
(365.3
)
 
$
361.5



 
Common
Stock
 
Additional
Paid-In
Capital
 
Treasury
Stock
 
Retained
Earnings
 
Accumulated
Other
Comprehensive
Loss
 
Total
Balance, December 31, 2018
$
0.4

 
$
110.1

 
$
(2.9
)
 
$
643.5

 
$
(210.9
)
 
$
540.2

Comprehensive income
 
 
 
 
 
 
7.6

 
14.7

 
22.3

Cumulative effect of change in accounting principle
 
 
 
 
 
 
(0.1
)
 
 
 
(0.1
)
Dividends on common stock ($0.72 per share)
 
 
0.1

 
 
 
(24.6
)
 
 
 
(24.5
)
Shares issued for stock units, net of shares withheld for taxes
 
 
 
 
(0.2
)
 
 
 
 
 
(0.2
)
Stock-based compensation
 
 
1.1

 
 
 
 
 
 
 
1.1

Balance, March 31, 2019
$
0.4

 
$
111.3

 
$
(3.1
)
 
$
626.4

 
$
(196.2
)
 
$
538.8


The accompanying notes are an integral part of the consolidated financial statements.


5


COMPASS MINERALS INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, in millions)
 
Three Months Ended
March 31,
 
2020
 
2019
Cash flows from operating activities:
 
 
 
Net earnings
$
27.6

 
$
7.6

Adjustments to reconcile net earnings to net cash flows provided by operating activities:
 
 
 
Depreciation, depletion and amortization
33.1

 
35.0

Finance fee amortization
0.8

 
0.7

Stock-based compensation
2.4

 
1.1

Deferred income taxes
7.5

 
(0.1
)
Net loss in equity investee
0.1

 
0.1

Unrealized foreign exchange (gain) loss
(18.0
)
 
5.1

Other, net
3.4

 
1.4

Changes in operating assets and liabilities:


 


Receivables
87.1

 
72.0

Inventories
36.6

 
41.0

Other assets
54.5

 
17.3

Accounts payable and accrued expenses and other current liabilities
(4.9
)
 
(46.7
)
Other liabilities
(1.6
)
 
(6.1
)
Net cash provided by operating activities
228.6

 
128.4

Cash flows from investing activities:


 


Capital expenditures
(25.3
)
 
(21.5
)
Other, net
(0.6
)
 
(0.3
)
Net cash used in investing activities
(25.9
)
 
(21.8
)
Cash flows from financing activities:


 


Proceeds from revolving credit facility borrowings
46.2

 
61.7

Principal payments on revolving credit facility borrowings
(147.2
)
 
(139.6
)
Proceeds from issuance of long-term debt
22.0

 
18.5

Principal payments on long-term debt
(18.7
)
 
(5.5
)
Dividends paid
(24.8
)
 
(24.6
)
Deferred financing costs
(0.1
)
 

Shares withheld to satisfy employee tax obligations
(0.1
)
 
(0.2
)
Other, net
(0.1
)
 
(0.3
)
Net cash used in financing activities
(122.8
)
 
(90.0
)
Effect of exchange rate changes on cash and cash equivalents
(4.8
)
 
0.2

Net change in cash and cash equivalents
75.1

 
16.8

Cash and cash equivalents, beginning of the year
34.7

 
27.0

Cash and cash equivalents, end of period
$
109.8

 
$
43.8


Supplemental cash flow information:
 

 
 

Interest paid, net of amounts capitalized
$
11.3

 
$
17.3

Income taxes paid, net of refunds
$
(37.7
)
 
$
10.2


The accompanying notes are an integral part of the consolidated financial statements.

6


COMPASS MINERALS INTERNATIONAL, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1.
Accounting Policies and Basis of Presentation:

Compass Minerals International, Inc. (“CMI”), through its subsidiaries (collectively, the “Company”), is a leading producer of essential minerals that solve nature’s challenges, including salt for winter roadway safety and other consumer, industrial and agricultural uses, specialty plant nutrition minerals that improve the quality and yield of crops, and specialty chemicals for water treatment and other industrial processes. The Company’s principal products are salt, consisting of sodium chloride and magnesium chloride; plant nutrients, consisting of sulfate of potash (“SOP”), secondary nutrients and micronutrients; and specialty chemicals. The Company also provides records management services to businesses located in the United Kingdom (the “U.K.”). The Company’s production sites are located in the United States (“U.S.”), Canada, Brazil and the U.K. Except where otherwise noted, references to North America include only the continental U.S. and Canada, and references to the U.K. include only England, Scotland and Wales. References to “Compass Minerals,” “our,” “us” and “we” refer to CMI and its consolidated subsidiaries.
 
CMI is a holding company with no significant operations other than those of its wholly-owned subsidiaries. The consolidated financial statements include the accounts of CMI and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

The Company uses the equity method of accounting for equity securities when it has significant influence or when it has more than a minor ownership interest or more than minor influence over an investee’s operations but does not have a controlling financial interest. Initial investments are recorded at cost (including certain transaction costs) and are adjusted by the Company’s share of the investees’ undistributed earnings and losses.

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company for the year ended December 31, 2019, as filed with the Securities and Exchange Commission in its Annual Report on Form 10-K. In the opinion of management, all adjustments, consisting of normal recurring adjustments considered necessary for a fair presentation, have been included.
 
The Company experiences a substantial amount of seasonality in its sales with respect to its deicing salt products. As a result, sales and operating earnings are generally higher in the first and fourth quarters and lower during the second and third quarters of each year. In particular, sales of highway and consumer deicing salt and magnesium chloride products vary based on the severity of the winter conditions in areas where the products are used. Following industry practice in North America and the U.K., the Company seeks to stockpile sufficient quantities of deicing salt throughout the second, third and fourth quarters to meet the estimated requirements for the upcoming winter season. Production of deicing salt can also vary based on the severity or mildness of the preceding winter season. Due to the seasonal nature of the deicing product lines, operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year.

The Company’s plant nutrition business is also seasonal. For example, the strongest demand for the Company’s plant nutrition products in Brazil typically occurs during the spring planting season. As a result, the Company and its customers generally build inventories during the low demand periods of the year to ensure timely product availability during the peak sales season. The seasonality of this demand results in the Company’s sales volumes and operating income for the Plant Nutrition South America segment usually being the highest during the third and fourth quarters of each year (as the spring planting season begins in September in Brazil).

Significant Accounting Policies

The Company’s significant accounting policies are detailed in “Note 2 – Summary of Significant Accounting Policies” within Item 8 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.

Recent Accounting Pronouncements

In January 2017, the Financial Accounting Standards Board (the “FASB”) issued guidance to simplify the accounting for goodwill impairment. The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed

7


the carrying amount of goodwill. All other goodwill impairment guidance remains largely unchanged. The adoption of this guidance on January 1, 2020 did not have an impact on the Company’s consolidated financial statements.

On January 1, 2020, the Company adopted guidance related to credit losses for financial instruments, which replaces the incurred lost methodology with a current expected credit loss methodology (“CECL”). The Company has determined that its trade receivables are the only financial instrument that is within scope of the new CECL guidance issued by FASB. The CECL methodology requires financial assets to be recorded at the net amount expected to be collected over the lifetime of the asset such that the estimated losses are accrued on the day the asset is acquired. The CECL methodology also requires financial assets to be aggregated and evaluated within pools with similar risk characteristics.
The Company has accrued an allowance on its trade receivables based on historical loss rates modified to consider supportable forecasts related to customer-specific and macroeconomic factors. For instance, the Company’s first quarter 2020 allowance for doubtful accounts considered the potential impact that the coronavirus (“COVID-19”) pandemic could have on the collectability of its outstanding receivables. The Company’s customer pools are comprised of North American highway deicing customers, North American consumer and industrial customers, Plant Nutrition North America customers, Plant Nutrition South America customers and customers whose outstanding receivable balances have been sent to collections. Customers grouped within these pools have similar risk characteristics. The Company’s allowance for doubtful accounts consists of estimates of expected credit losses and accruals for returns and allowances. At the transition date of January 1, 2020, the implementation of CECL had an immaterial impact of less than $0.1 million on the Company’s consolidated financial statements. Under CECL, the Company had an allowance for doubtful accounts of $9.4 million and $7.9 million as of January 1, 2020, and March 31, 2020, respectively.
2.    Revenue Recognition:

Nature of Products and Services

The Company’s Salt segment products include salt and magnesium chloride for use in road deicing and dust control, food processing, water softeners, and agricultural and industrial applications. The Company’s plant nutrition products include SOP, secondary nutrients, micronutrients and chemicals for the industrial chemical industry. In the U.K., the Company operates a records management business utilizing excavated areas of the Winsford salt mine with one other location in London, England.

Identifying the Contract

The Company accounts for a customer contract when there is approval and commitment from both parties, the rights of the parties and payment terms are identified, the contract has commercial substance and collectability of consideration is probable.

Identifying the Performance Obligations

At contract inception, the Company assesses the goods and services it has promised to its customers and identifies a performance obligation for each promise to transfer to the customer a distinct good or service (or bundle of goods or services). Determining whether products and services are considered distinct performance obligations that should be accounted for separately or aggregated together may require significant judgment.

Identifying and Allocating the Transaction Price

The Company’s revenues are measured based on consideration specified in the customer contract, net of any sales incentives and amounts collected on behalf of third parties such as sales taxes. In certain cases, the Company’s customer contracts may include promises to transfer multiple products and services to a customer. For multiple-element arrangements, the Company generally allocates the transaction price to each performance obligation in proportion to its stand-alone selling price.

When Performance Obligations Are Satisfied

The vast majority of the Company’s revenues are recognized at a point in time when the performance obligations are satisfied based upon transfer of control of the product or service to a customer. To determine when the control of goods is transferred, the Company typically assesses, among other things, the shipping terms of the contract, as shipping is an indicator of transfer of control. Some of the Company’s products are sold when the control of the goods transfers to the customer at the time of shipment. There are also instances when the Company provides shipping services to deliver its products. Shipping and handling costs that occur before the customer obtains control of the goods are deemed to be fulfillment activities and are accounted for as fulfillment costs. The Company recognizes shipping and handling costs that are incurred after the customer obtains control of the goods as fulfillment costs which are accrued at the time of revenue recognition.

8



Significant Payment Terms

The customer contract states the final terms of the sale, including the description, quantity and price of each product or service purchased. Payment is typically due in full within 30 days of delivery. The Company does not adjust the consideration for the effects of a significant financing component if the Company expects, at contract inception, that the period between when the good or service is transferred to the customer and when the customer pays for that good or service will be one year or less.

Refunds, Returns and Warranties

The Company’s products are generally not sold with a right of return and the Company does not generally provide credits or incentives, which may be required to be accounted for as variable consideration when estimating the amount of revenue to be recognized. The Company uses historical experience to estimate accruals for refunds due to manufacturing or other defects.

See Note 10 for disaggregation of revenue by segment, type and geographical region.

3.
Leases:

In February 2016, the FASB issued guidance which requires lessees to recognize on their balance sheet a right-of-use asset which represents a lessee’s right to use the underlying asset and a lease liability which represents a lessee’s obligation to make lease payments for the right to use the asset. In addition, the guidance requires expanded qualitative and quantitative disclosures. The Company has adopted this guidance beginning in the first quarter of 2019, using a modified retrospective transition method, which required the cumulative effect of this change in accounting of $0.1 million to be recorded as an adjustment to beginning retained earnings. The Company elected the package of transition provisions available for existing contracts, which allowed entities to carryforward the historical assessment of whether the contract contained a lease and the lease classification.

The Company enters into leases for warehouses and depots, rail cars, vehicles, mobile equipment, office space and certain other types of property and equipment. The Company determines whether an arrangement is or contains a lease at the inception of the contract. The right-of-use asset and lease liability are recognized based on the present value of the future minimum lease payments over the estimated lease term. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. The Company estimates its incremental borrowing rate for each lease based upon the estimated lease term, the type of asset and the location of the leased asset. The most significant judgments in the application of the FASB guidance include whether a contract contains a lease and the lease term.

Leases with an initial term of 12 months or less are not recorded on the Company’s Consolidated Balance Sheets. The Company recognizes lease expense for these short-term leases on a straight-line basis over the lease term. Many of the Company’s leases include one or more options to renew and extend the initial lease term. The exercise of lease renewal options is generally at the Company’s discretion. The lease term includes renewal periods in only those instances in which the Company determines it is reasonably assured of renewal.
 
The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. In these instances, the assets are depreciated over the useful life of the asset.

The Company has elected the practical expedient available under the FASB guidance to not separate lease and nonlease components on all of its lease categories. As a result, many of the Company’s leases include variable payments for services (such as handling or storage) or payments based on the usage of the asset. In addition, certain of the Company’s lease agreements include rental payments that are adjusted periodically for inflation. The Company’s lease agreements do not contain any material residual value guarantees or any material restrictive covenants. The Company’s sublease income is immaterial.


9


The Company’s Consolidated Balance Sheets includes the following (in millions):
 
Consolidated Balance Sheets Location
March 31,
2020
December 31,
2019
Assets
 
 
 
Operating lease assets
Other assets
$
49.7

$
53.7

Finance lease assets
Property, plant and equipment, net
5.9

5.8

Total leased assets
 
$
55.6

$
59.5

Liabilities
 
 
 
Current liabilities:
 
 
 
Operating
Accrued expenses and other current liabilities
$
9.5

$
12.8

Finance
Accrued expenses and other current liabilities
1.7

1.1

Noncurrent liabilities:
 
 
 
Operating
Other noncurrent liabilities
40.4

41.0

Finance
Other noncurrent liabilities
5.3

6.2

Total lease liabilities
 
$
56.9

$
61.1


The Company’s components of lease cost are as follows (in millions):
 
Three Months Ended March 31,
 
2020
2019
Finance lease cost:
 
 
Amortization of lease assets
$
0.5

$
0.3

Interest on lease liabilities
0.1

0.2

Operating lease cost
4.6

4.8

Variable lease cost(a)
5.1

6.1

Net lease cost
$
10.3

$
11.4

(a)
Short-term leases are immaterial and included in variable lease cost.

Maturities of lease liabilities under the new guidance (“Topic 842”) are as follows (in millions):
Topic 842
March 31, 2020
Operating Leases
Finance Leases
Total
Remainder of 2020
$
8.7

$
1.6

$
10.3

2021
10.1

1.6

11.7

2022
7.5

0.9

8.4

2023
6.2

0.9

7.1

2024
5.3

0.9

6.2

After 2024
22.4

2.8

25.2

Total lease payments
60.2

8.7

68.9

Less: Interest
(10.3
)
(1.7
)
(12.0
)
Present value of lease liabilities
$
49.9

$
7.0

$
56.9


10



Topic 842
December 31, 2019
Operating Leases
Finance Leases
Total
2020
$
13.0

$
1.6

$
14.6

2021
10.0

1.3

11.3

2022
7.5

1.1

8.6

2023
6.3

1.1

7.4

2024
5.3

1.1

6.4

After 2024
22.8

3.3

26.1

Total lease payments
64.9

9.5

74.4

Less: Interest
(11.1
)
(2.2
)
(13.3
)
Present value of lease liabilities
$
53.8

$
7.3

$
61.1



Supplemental lease term and discount rate information related to leases is as follows:

March 31, 2020
December 31, 2019
Weighted-average remaining lease term (years)
 
 
Operating leases
7.7

7.7

Finance leases
6.2

7.2

Weighted-average discount rate
 
 
Operating leases
4.3
%
4.3
%
Finance leases
7.1
%
7.6
%

Supplemental cash flow information related to leases is as follows (in millions):
 
Three Months Ended March 31,
 
2020
2019
Cash paid for amounts included in the measurement of lease liabilities
 
 
Operating cash flows from operating leases
$
4.5

$
4.9

Operating cash flows from finance leases
0.1

0.2

Financing cash flows from finance leases
0.5

0.3

Leased assets obtained in exchange for new operating lease liabilities
1.0

2.4

Leased assets obtained in exchange for new finance lease liabilities
1.2




4.
Inventories:
 
Inventories consist of the following (in millions):
 
March 31,
2020
 
December 31,
2019
Finished goods
$
185.6

 
$
235.3

Raw materials and supplies
68.6

 
76.2

Total inventories
$
254.2

 
$
311.5




11


5.
Property, Plant and Equipment, Net:
 
Property, plant and equipment, net, consists of the following (in millions):
 
March 31,
2020
 
December 31,
2019
Land, buildings and structures, and leasehold improvements
$
578.3

 
$
596.0

Machinery and equipment
974.8

 
1,001.9

Office furniture and equipment
62.4

 
60.7

Mineral interests
165.9

 
171.1

Construction in progress
136.2

 
141.3

 
1,917.6

 
1,971.0

Less accumulated depreciation and depletion
(963.8
)
 
(940.2
)
Property, plant and equipment, net
$
953.8

 
$
1,030.8



6.
Goodwill and Intangible Assets, Net:

Amounts related to the Company’s amortization of intangible assets are as follows (in millions):
 
 
Three Months Ended
March 31,
 
 
2020
 
2019
Aggregate amortization expense
 
$
3.2

 
$
3.6



Amounts related to the Company’s goodwill are as follows (in millions):
 
March 31,
2020
 
December 31,
2019
Goodwill - Plant Nutrition North America Segment
$
50.5

 
$
55.4

Goodwill - Plant Nutrition South America Segment
218.4

 
281.6

Other
5.8

 
6.0

Total
$
274.7

 
$
343.0



The change in goodwill between December 31, 2019 and March 31, 2020 was due to the impact from translating foreign-denominated amounts to U.S. dollars.

7.
Income Taxes:

The Company’s effective income tax rate differs from the U.S. statutory federal income tax rate primarily due to U.S. statutory depletion, state income taxes (net of federal tax benefit), foreign income, mining and withholding taxes, global intangible low-taxed income and interest expense recognition differences for book and tax purposes. The Company’s effective rate is impacted by permanent tax deductions which have a less favorable impact as pretax income increases.

The Company had $14.8 million and $18.8 million as of March 31, 2020 and December 31, 2019, respectively, of gross foreign federal net operating loss (“NOL”) carryforwards that have no expiration date, $1.2 million and $1.7 million, respectively, of gross foreign federal NOL carryforwards which expire beginning in 2033 and $0.2 million and $0.3 million, respectively, of net operating tax-effected state NOL carryforwards which expire beginning in 2027.
 
Canadian provincial tax authorities have challenged tax positions claimed by one of the Company’s Canadian subsidiaries and have issued tax reassessments for years 2002-2014. The reassessments are a result of ongoing audits and total $120.4 million, including interest, through March 31, 2020. The Company disputes these reassessments and will continue to work with the appropriate authorities in Canada to resolve the dispute. There is a reasonable possibility that the ultimate resolution of this dispute, and any related disputes for other open tax years, may be materially higher or lower than the amounts the Company has reserved for such disputes. In connection with this dispute, local regulations require the Company to post security with the tax authority

12


until the dispute is resolved. The Company has posted collateral in the form of an $89.6 million performance bond and has paid $34.8 million to the Canadian tax authorities (most of which is recorded in other assets in the Consolidated Balance Sheets).
 
The Company expects that it will be required by local regulations to provide security for additional interest on the above unresolved disputed amounts and for any future reassessments issued by these Canadian tax authorities in the form of cash, letters of credit, performance bonds, asset liens or other arrangements agreeable with the tax authorities until the disputes are resolved.

The Company expects that the ultimate outcome of these matters will not have a material impact on its results of operations or financial condition. However, the Company can provide no assurance as to the ultimate outcome of these matters, and the impact could be material if they are not resolved in the Company’s favor. As of March 31, 2020, the Company believes it has adequately reserved for these reassessments.
 
Additionally, the Company has other uncertain tax positions as well as assessments and disputed positions with taxing authorities in its various jurisdictions, which are consistent with those matters disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.

Settlements

In the fourth quarter of 2017, the Company, the Canadian Revenue Authority (“CRA”) and the U.S. Internal Revenue Service (“IRS”) reached a settlement agreement on transfer pricing issues for the Company’s 2007-2012 tax years. As a result of this settlement agreement, the Company recognized $13.8 million of tax expense in its 2017 Consolidated Statements of Operations related to the Company’s Canadian tax positions for the years 2007-2016. The recording of this settlement resulted in increased sales for the Company’s Canadian subsidiary of $85.7 million and increased offsetting expenses for the Company’s U.S. subsidiary in 2017 causing a domestic loss and significant foreign income. During 2018, in accordance with the settlement agreement, the Company’s U.S. subsidiary made intercompany cash payments of $85.7 million to its Canadian subsidiary and tax payments to Canadian taxing authorities of $17.5 million. The remaining liability was satisfied in 2019 with tax payments of $5.3 million. Corresponding tax refunds of $21.4 million were received in 2019 from U.S. taxing authorities, with the remaining refund of approximately $1.6 million expected in 2020 (recorded in other current assets in the Consolidated Balance Sheets).

In the fourth quarter of 2018, the Company, the CRA and the IRS reached a settlement agreement on transfer pricing and management fees as part of an advanced pricing agreement that covers tax years 2013-2021. The tax expense was previously recognized in 2017, however the recording of this settlement resulted in increased sales for the Company’s Canadian subsidiary of $106.1 million and offsetting expenses for the Company’s U.S. subsidiary in 2018 causing a domestic loss and significant foreign income. During 2019, in accordance with the settlement agreement, the Company’s U.S. subsidiary made intercompany cash payments of $106.1 million to its Canadian subsidiary and tax payments to Canadian taxing authorities of $29.9 million, with the remaining $1.3 million of tax payments to be paid during 2020. Corresponding tax refunds of $59.2 million have been received as of March 31, 2020 from U.S. taxing authorities, of which $55 million was received during the first quarter of 2020, with the remaining $2.4 million expected in 2020 (recorded in other current assets in its Consolidated Balance Sheets).

13


8.
Long-Term Debt:
 
Long-term debt consists of the following (in millions):
 
March 31,
2020
 
December 31,
2019
4.875% Senior Notes due July 2024
$
250.0

 
$
250.0

Term Loan due January 2025
397.5

 
400.0

Revolving Credit Facility due January 2025
59.0

 
160.0

6.75% Senior Notes due December 2027
500.0

 
500.0

3.7% Banco Itaú loan due March 2020

 
15.4

Banco Santander loan due October 2020
12.5

 
16.2

Banco Itaú loan due February 2021
9.4

 

Banco Rabobank loan due July 2021
13.5

 
17.4

Banco Santander loan due September 2021
15.4

 
19.9

Banco do Brasil loan due September 2021
9.6

 
12.4

Banco Rabobank loan due November 2021
13.5

 
17.4

Banco Santander loan due December 2021
11.6

 
14.9

Banco Votorantim loan due February 2022
7.7

 

Banco Santander loan due March 2022
2.9

 

Financiadora de Estudos e Projetos loan due November 2023
5.2

 
7.2


1,307.8

 
1,430.8

Less unamortized debt issuance costs
(14.0
)
 
(14.8
)
Total debt
1,293.8

 
1,416.0

Less current portion
(40.1
)
 
(52.1
)
Long-term debt
$
1,253.7

 
$
1,363.9




In the first quarter of 2020, the Company entered into three loans totaling $20.0 million which mature between February 2021 and March 2022, respectively. Two of the loans were denominated in Brazilian reais and one loan was denominated in euros. In connection with the loan denominated in euros, the Company entered into a swap to exchange principal and interest payments denominated in euros to Brazilian reais (see Note 12). These loans bear interest ranging from 143% - 150% of CDI. As of March 31, 2020, the weighted average interest rate of all the Company’s outstanding debt was approximated 5.69%.

During the first quarter of 2020, the Company sold approximately $3.4 million of Brazilian receivables for $3.3 million. The proceeds of the transaction were used to maintain liquidity for working capital needs. The Company is contingently liable for up to 20% of the sale balance up to $0.7 million if the banks are unable to collect on these accounts.

As of March 31, 2020, the term loans and revolving credit facility under the Company’s credit agreement were secured by substantially all existing and future U.S. assets, the Goderich mine in Ontario, Canada and capital stock of certain subsidiaries.

9.
Commitments and Contingencies:

The Wisconsin Department of Agriculture, Trade and Consumer Protection (“DATCP”) and the Wisconsin Department of Natural Resources (“DNR”) have information indicating that agricultural chemicals are present within the subsurface area of the Company’s property located in Kenosha, Wisconsin. The agricultural chemicals were used by previous owners and operators of the site. None of the identified chemicals have been used in association with the Company’s operations since it acquired the property in 2002. DATCP and DNR have directed the Company to conduct further investigations into the environmental conditions at the Kenosha property. The Company continues on-property investigations and has provided the findings to DATCP and DNR as they have become available. All investigations and mitigation activities to date, and any potential future remediation work, are being conducted under the Wisconsin Agricultural Chemical Cleanup Program, which provides for reimbursement of some of the costs.

The Company conducts business operations in several countries and is subject to various federal and local labor, social security, environmental and tax laws. While the Company believes it complies with such laws, they are complex and subject to interpretation.

14


In addition to the tax assessments discussed in Note 7, the Company’s Brazilian subsidiaries are party to administrative tax proceedings and claims which totaled $7.9 million and $15.8 million as of March 31, 2020 and December 31, 2019, respectively, and relate primarily to value added tax, state tax (ICMS) and social security tax (PIS and COFINS) assessments. The Company has assessed the likelihood of a loss at less than probable and therefore, has not established a reserve for these matters. The Company also assumed liabilities for labor-related matters in connection with the 2016 acquisition of Compass Minerals South America, which are primarily related to compensation, labor benefits and consequential tax claims that totaled $3.9 million and $5.6 million as of March 31, 2020 and December 31, 2019, respectively. The Company believes the maximum exposure for these other labor matters totaled approximately $18 million and $25 million as of March 31, 2020 and December 31, 2019, respectively.

The Division of Enforcement of the U.S. Securities and Exchange Commission (“SEC”) is investigating the Company’s disclosures concerning the operation of the Goderich mine. The Company has cooperated with this investigation and will continue to do so. While it is not possible to predict the timing or the outcome of the SEC inquiry, the Company believes that this matter will not have a material impact on its results of operation, cash flows or financial position.

The Company is also involved in legal and administrative proceedings and claims of various types from the ordinary course of the Company’s business.

Management cannot predict the outcome of legal claims and proceedings with certainty. Nevertheless, management believes the outcome of legal proceedings and claims, which are pending or known to be threatened, even if determined adversely, will not, individually or in the aggregate, have a material adverse effect on the Company’s results of operations, cash flows or financial position.

10.
Operating Segments:
 
The Company’s reportable segments are strategic business units that offer different products and services, and each business requires different technology and marketing strategies. The Company has three reportable segments: Salt, Plant Nutrition North America and Plant Nutrition South America. The Salt segment produces and markets salt, consisting of sodium chloride and magnesium chloride, for use in road deicing for winter roadway safety and for dust control, food processing, water softeners and other consumer, agricultural and industrial applications. Plant nutrients, including SOP, secondary nutrients and micronutrients are produced and marketed through the Plant Nutrition North America segment. The Plant Nutrition South America segment operates two primary businesses in Brazil – agricultural productivity and chemical solutions. The agricultural productivity division manufactures and distributes a broad offering of specialty plant nutrition solution-based products that are used in direct soil and foliar applications, as well as through irrigation systems and for seed treatment. The chemical solutions division manufactures and markets specialty chemicals for the industrial chemical industry.

Segment information is as follows (in millions):
Three Months Ended March 31, 2020
 
Salt
 
Plant
Nutrition North America
 
Plant
Nutrition South America
 
Corporate
& Other
(a)
 
Total
Sales to external customers
 
$
287.8

 
$
60.6

 
$
62.8

 
$
2.7

 
$
413.9

Intersegment sales
 

 
0.3

 
0.1

 
(0.4
)
 

Shipping and handling cost
 
89.8

 
9.0

 
3.0

 

 
101.8

Operating earnings (loss)
 
56.9

 
5.2

 
0.3

 
(18.2
)
 
44.2

Depreciation, depletion and amortization
 
14.6

 
10.5

 
5.0

 
3.0

 
33.1

Total assets (as of end of period)
 
956.5

 
552.3

 
561.0

 
41.0

 
2,110.8



15


Three Months Ended March 31, 2019
 
Salt
 
Plant
Nutrition North America
 
Plant
Nutrition South America
 
Corporate
& Other
(a)
 
Total
Sales to external customers
 
$
306.4

 
$
37.2

 
$
57.7

 
$
2.4

 
$
403.7

Intersegment sales
 

 
0.5

 
1.5

 
(2.0
)
 

Shipping and handling cost
 
103.7

 
6.0

 
3.2

 

 
112.9

Operating earnings (loss) 
 
52.3

 
(1.6
)
 
(2.6
)
 
(14.9
)
 
33.2

Depreciation, depletion and amortization
 
15.3

 
11.6

 
5.6

 
2.5

 
35.0

Total assets (as of end of period)
 
889.7

 
594.1

 
710.6

 
114.2

 
2,308.6


Disaggregated revenue by product type is as follows (in millions):
Three Months Ended March 31, 2020

Salt

Plant
Nutrition North America

Plant
Nutrition South America

Corporate
& Other
(a)

Total
Highway Deicing Salt

$
215.1


$


$


$


$
215.1

Consumer & Industrial Salt

72.7








72.7

SOP and Specialty Plant Nutrients



60.9


41.1




102.0

Industrial Chemicals





21.8




21.8

Eliminations & Other



(0.3
)

(0.1
)

2.7


2.3

Sales to external customers

$
287.8


$
60.6


$
62.8


$
2.7


$
413.9


Three Months Ended March 31, 2019
 
Salt
 
Plant
Nutrition North America
 
Plant
Nutrition South America
 
Corporate
& Other(a)
 
Total
Highway Deicing Salt
 
$
218.7

 
$

 
$

 
$

 
$
218.7

Consumer & Industrial Salt
 
87.7

 

 

 

 
87.7

SOP and Specialty Plant Nutrients
 

 
37.7

 
36.6

 

 
74.3

Industrial Chemicals
 

 

 
22.6

 

 
22.6

Eliminations & Other
 

 
(0.5
)
 
(1.5
)
 
2.4

 
0.4

Sales to external customers
 
$
306.4

 
$
37.2

 
$
57.7

 
$
2.4

 
$
403.7

(a)
Corporate and other includes corporate entities, records management operations and other incidental operations and eliminations. Operating earnings (loss) for corporate and other includes indirect corporate overhead, including costs for general corporate governance and oversight, as well as costs for the human resources, information technology, legal and finance functions.

The Company’s revenue by geographic area is as follows (in millions):
 
 
Three Months Ended March 31,
Revenue
 
2020
 
2019
United States(a)
 
$
257.9

 
$
238.3

Canada
 
77.4

 
87.4

Brazil
 
62.1

 
55.7

United Kingdom
 
11.8

 
17.3

Other
 
4.7

 
5.0

Total revenue
 
$
413.9

 
$
403.7


(a)
United States sales exclude product sold to foreign customers at U.S. ports.


16


11.
Stockholders’ Equity and Equity Instruments:

In May 2015, the Company’s stockholders approved the 2015 Incentive Award Plan (as amended, the “2015 Plan”), which authorizes the issuance of 3,000,000 shares of Company common stock. Since the date the 2015 Plan was approved, the Company ceased issuing equity awards under the 2005 Incentive Award Plan (as amended, the “2005 Plan”). The 2005 Plan and 2015 Plan allow for grants of equity awards to executive officers, other employees and directors, including restricted stock units (“RSUs”), performance stock units (“PSUs”), stock options and deferred stock units. The grants occur following approval by the compensation committee of the Company’s board of directors, with the amount and terms communicated to employees shortly thereafter. 

Options

Most of the stock options granted under the 2005 Plan and 2015 Plan vest ratably, in tranches, over a four-year service period. Unexercised options expire after seven years. Options do not have dividend or voting rights. Upon vesting, each option can be exercised to purchase one share of the Company’s common stock. The exercise price of options is equal to the closing stock price on the grant date.

To estimate the fair value of options on the grant date, the Company uses the Black-Scholes option valuation model. Award recipients are grouped according to expected exercise behavior. Unless better information is available to estimate the expected term of the options, the estimate is based on historical exercise experience. The risk-free rate, using U.S. Treasury yield curves in effect at the time of grant, is selected based on the expected term of each group. The Company’s historical stock price is used to estimate expected volatility. The fair value and inputs used to calculate fair value for options granted in 2020 are included in the table below:
 
 
Fair value of options granted
$10.91
Exercise price
$58.91
Expected term (years)
4.75
Expected volatility
29.3%
Dividend yield
3.5%
Risk-free rate of return
1.6%


RSUs

Typically, the RSUs granted under the 2015 Plan vest after three years of service. RSUs entitle the holders to one share of common stock for each vested RSU. Unvested RSUs do not have voting rights but are entitled to receive non-forfeitable dividends (generally after a performance hurdle has been satisfied for the year of the grant) or other distributions equal to those declared on the Company’s common stock for RSUs that are earned as a result of the satisfaction of the performance hurdle. The closing stock price on the grant date is used to determine the fair value of RSUs.

PSUs

The PSUs granted under the 2015 Plan are either total shareholder return PSUs (“TSR PSUs”) or return on invested capital PSUs (“ROIC PSUs”). The actual number of shares of the Company’s common stock that may be earned with respect to TSR PSUs is calculated by comparing the Company’s total shareholder return to the total shareholder return for each company comprising the Russell 3000 Index (for TSR PSUs granted in 2017 and earlier) or the Company’s peer group (for TSR PSUs granted in 2018 and later) over the three-year performance period and may range from 0% to 200% of the target number of shares based upon the attainment of these market conditions. The actual number of shares of common stock that may be earned with respect to ROIC PSUs is calculated based on the average of the Company’s annual return on invested capital for each year in the three-year performance period and may range from 0% to 200% of the target number of shares based upon the attainment of these performance conditions.

PSUs represent a target number of shares of the Company’s common stock that may be earned before adjustment based upon the attainment of certain conditions. Holders of PSUs do not have voting rights but are entitled to receive non-forfeitable dividends or other distributions equal to those declared on the Company’s common stock for PSUs that are earned, which are paid when the shares underlying the PSUs are paid.

To estimate the fair value of the TSR PSUs on the grant date, the Company uses a Monte-Carlo simulation model, which simulates future stock prices of the Company as well as the companies comprising the Russell 3000 Index or the Company’s peer group

17


depending on the year granted. This model uses historical stock prices to estimate expected volatility and the Company’s correlation to the Russell 3000 Index or peer group. The risk-free rate was determined using the same methodology as the option valuations as discussed above. The Company’s closing stock price on the grant date was used to estimate the fair value of the ROIC PSUs. The Company will adjust the expense of the ROIC PSUs based upon its estimate of the number of shares that will ultimately vest at each interim date during the vesting period.

During the three months ended March 31, 2020, the Company reissued the following number of shares from treasury stock: no shares related to the exercise of stock options, 4,517 shares related to the release of RSUs which vested and 3,377 shares related to stock payments. In 2019, the Company issued 32,197 shares from treasury stock. The Company withheld 1,479 shares with a fair value of $0.1 million related to the vesting of RSUs during the first three months of 2020. The fair value of the shares were valued at the closing price at the vesting date and represent the employee tax withholding for the employee’s compensation. The Company recognized a tax deficiency of $0.2 million from its equity compensation awards as an increase to income tax expense during the first three months of 2020. During the first three months of 2020 and 2019, the Company recorded $2.9 million (includes $0.5 million to be paid in cash) and $1.1 million, respectively, of compensation expense pursuant to its stock-based compensation plans. No amounts have been capitalized. The following table summarizes stock-based compensation activity during the three months ended March 31, 2020:
 
 
Stock Options
 
RSUs
 
PSUs(a)
 
 
Number
 
Weighted-average
exercise price
 
Number
 
Weighted-average
fair value
 
Number
 
Weighted-average
fair value
Outstanding at December 31, 2019
 
887,867

 
$
64.21

 
217,413

 
$
52.07

 
179,397

 
$
61.43

Granted
 
94,945

 
58.91

 
83,337

 
58.92

 
69,635

 
82.38

Exercised(b)
 

 

 

 

 

 

Released from restriction(b)
 

 

 
(4,517
)
 
39.75

 

 

Cancelled/expired
 
(64,666
)
 
72.67

 
(27,981
)
 
50.18

 
(26,899
)
 
67.55

Outstanding at March 31, 2020
 
918,146

 
$
63.07

 
268,252

 
$
54.61

 
222,133

 
$
67.26

(a)
Until the performance period is completed, PSUs are included in the table at the target level at their grant date and at that level represent one share of common stock per PSU.
(b)
Common stock issued for exercised options and for vested and earned RSUs and PSUs was issued from treasury stock.

Other Comprehensive (Loss) Income

The Company’s comprehensive (loss) income is comprised of net earnings, net amortization of the unrealized loss of the pension obligation, the change in the unrealized gain on natural gas and foreign currency cash flow hedges and foreign currency translation adjustments. The components of and changes in accumulated other comprehensive loss (“AOCL”) as of and for the three months ended March 31, 2020 and 2019, are as follows (in millions):
Three Months Ended March 31, 2020(a)
Gains and
(Losses) on
Cash Flow
Hedges
 
Defined
Benefit
Pension
 
Foreign
Currency
 
Total
Beginning balance
$
(0.6
)
 
$
(6.9
)
 
$
(184.6
)
 
$
(192.1
)
Other comprehensive income (loss) before reclassifications(b)
2.7

 

 
(173.5
)
 
(170.8
)
Amounts reclassified from accumulated other comprehensive loss
(2.6
)
 
0.2

 

 
(2.4
)
Net current period other comprehensive income (loss)
0.1

 
0.2

 
(173.5
)
 
(173.2
)
Ending balance
$
(0.5
)
 
$
(6.7
)
 
$
(358.1
)
 
$
(365.3
)


18


Three Months Ended March 31, 2019(a)
Gains and
(Losses) on
Cash Flow
Hedges
 
Defined
Benefit
Pension
 
Foreign
Currency
 
Total
Beginning balance
$
(0.7
)
 
$
(4.5
)
 
$
(205.7
)
 
$
(210.9
)
Other comprehensive income before reclassifications(b)
0.2

 

 
14.5

 
14.7

Amounts reclassified from accumulated other comprehensive loss
(0.1
)
 
0.1

 

 

Net current period other comprehensive income
0.1

 
0.1

 
14.5

 
14.7

Ending balance
$
(0.6
)
 
$
(4.4
)
 
$
(191.2
)
 
$
(196.2
)
(a)
With the exception of the cumulative foreign currency translation adjustment, for which no tax effect is recorded, the changes in the components of accumulated other comprehensive loss presented in the tables above are reflected net of applicable income taxes.
(b)
The Company recorded a foreign exchange gain (loss) of $(75.5) million and $2.3 million in the three months ended March 31, 2020 and 2019, respectively, in accumulated other comprehensive loss related to intercompany notes which were deemed to be of a long-term investment nature.

The amounts reclassified from AOCL to expense (income) for the three months ended March 31, 2020 and 2019, are shown below (in millions):
 
 
 
 
 
 
 
Amount Reclassified from AOCL
 
 
 
Three Months Ended
March 31, 2020
 
Three Months Ended
March 31, 2019
 
Line Item Impacted in the
Consolidated Statements of Operations
Gains (losses) on cash flow hedges:
 
 
 
 
 
Natural gas instruments
$
(0.3
)
 
$
(0.1
)
 
Product cost
Foreign currency contracts
(3.6
)
 
(0.1
)
 
Interest expense
Income tax expense
1.3

 
0.1

 
 
Reclassifications, net of income taxes
(2.6
)
 
(0.1
)
 
 
Amortization of defined benefit pension:
 

 
 
 
 
Amortization of loss
$
0.2

 
$
0.1

 
Product cost
Reclassifications, net of income taxes
0.2

 
0.1

 
 
Total reclassifications, net of income taxes
$
(2.4
)
 
$

 
 


12.
Derivative Financial Instruments:
 
The Company is subject to various types of market risks, including interest rate risk, foreign currency exchange rate transaction and translation risk and commodity pricing risk. Management may take actions to mitigate the exposure to these types of risks, including entering into forward purchase contracts and other financial instruments. Currently, the Company manages a portion of its commodity pricing and foreign currency exchange rate risks by using derivative instruments. The Company does not seek to engage in trading activities or take speculative positions with any financial instrument arrangement. The Company has entered into natural gas derivative instruments and foreign currency derivative instruments with counterparties it views as creditworthy. However, the Company does attempt to mitigate its counterparty credit risk exposures by, among other things, entering into master netting agreements with some of these counterparties. The Company records derivative financial instruments as either assets or liabilities at fair value in the Consolidated Balance Sheets.

Derivatives qualify for treatment as hedges when there is a high correlation between the change in fair value of the derivative instrument and the related change in value of the underlying hedged item. Depending on the exposure being hedged, the Company must designate the hedging instrument as a fair value hedge, a cash flow hedge or a net investment in foreign operations hedge. For the qualifying derivative instruments that have been designated as hedges, the change in fair value is recognized through earnings when the underlying transaction being hedged affects earnings, allowing a derivative’s gains and losses to offset related results from the hedged item in the statements of operations. Any ineffectiveness related to these hedges was not material for any of the periods presented. For derivative instruments that have not been designated as hedges, the entire change in fair value is recorded through earnings in the period of change.

Natural Gas Derivative Instruments

Natural gas is consumed at several of the Company’s production facilities, and changes in natural gas prices impact the Company’s operating margin. The Company’s objective is to reduce the earnings and cash flow impacts of changes in market prices of natural gas by fixing the purchase price of up to 90% of its forecasted natural gas usage. It is the Company’s policy to consider hedging

19


portions of its natural gas usage up to 36 months in advance of the forecasted purchase. As of March 31, 2020, the Company had entered into natural gas derivative instruments to hedge a portion of its natural gas purchase requirements through December 2021. As of March 31, 2020 and December 31, 2019, the Company had agreements in place to hedge forecasted natural gas purchases of 2.8 million MMBtus. All natural gas derivative instruments held by the Company as of March 31, 2020 and December 31, 2019 qualified and were designated as cash flow hedges. As of March 31, 2020, the Company expects to reclassify from accumulated other comprehensive loss to earnings during the next twelve months $0.6 million of net losses on derivative instruments related to its natural gas hedges.

Foreign Currency Derivatives Not Designated as Hedges

In March 2020, the Company entered into forward instruments to swap currency denominated in U.S. dollars to Canadian dollars for a future intercompany payment from a U.S. subsidiary to a Canadian subsidiary. These instruments mature in April 2020 with a combined notional amounts of $89.9 million. The objective of the instruments was to mitigate the foreign currency fluctuation risk related to intercompany payments denominated in a currency other than U.S. dollars, the Company’s functional currency. The instrument was not designated as a hedge. During the three months ended March 31, 2020, the Company recognized a loss of $5.3 million in loss on foreign exchange in its Consolidated Statements of Operations for these agreements.
 
Foreign Currency Derivatives Designated as Hedges

The Company has entered into U.S. dollar-denominated debt instruments to provide funds for its operations in Brazil. The Company may also concurrently enter into foreign currency agreements whereby the Company agrees to swap interest and principal payments on loans denominated in U.S. dollars for principal and interest payments denominated in Brazilian reais, its Brazil subsidiary’s functional currency. The objective of the swap agreements is to mitigate the foreign currency fluctuation risk related to holding debt denominated in a currency other than the Company’s Brazil subsidiary’s functional currency. As of March 31, 2020, the Company had a swap agreement in place to hedge $9.4 million of a loan denominated in a currency other than its Brazil subsidiary’s functional currency. Payments on this loan are due on various dates extending through February 2021. As of March 31, 2020, this foreign currency derivative instrument qualified and was designated as a cash flow hedge. As of March 31, 2020, the Company expects to reclassify from accumulated other comprehensive loss to earnings during the next twelve months $1.7 million of net gains on derivative instruments related to this foreign currency swap agreement.

The following tables present the fair value of the Company’s hedged items as of March 31, 2020 and December 31, 2019 (in millions):
 
 
Asset Derivatives
 
Liability Derivatives
Derivatives designated as hedging instruments:
 
Consolidated Balance Sheets Location
 
March 31, 2020
 
Consolidated Balance Sheets Location
 
March 31, 2020
Commodity contracts
 
Other current assets
 
$
0.3

 
Accrued expenses and other current liabilities
 
$
0.9

Commodity contracts
 
Other assets
 

 
Other noncurrent liabilities
 
0.1

Swap contracts
 
Other current assets
 
1.7

 
Accrued expenses and other current liabilities
 

Total derivatives designated as hedging instruments(a)(b)
 
 
 
$
2.0

 
 
 
$
1.0

(a)
The Company has master netting agreements with both of its commodity hedge counterparties and accordingly has netted in its Consolidated Balance Sheets $0.3 million of its commodity contracts that are in a receivable position against its contracts in payable positions.
(b)
The Company has commodity hedge agreements with two counterparties and a foreign currency swap agreement with one counterparty. Amounts recorded as liabilities for the Company’s commodity contracts are payable to both counterparties and amounts recorded as assets for the Company’s foreign currency swap agreements are receivable from one counterparty. 


20


 
 
Asset Derivatives
 
Liability Derivatives
Derivatives designated as hedging instruments:
 
Consolidated Balance Sheets Location
 
December 31, 2019
 
Consolidated Balance Sheets Location
 
December 31, 2019
Commodity contracts
 
Other current assets
 
$
0.3

 
Accrued expenses and other current liabilities
 
$
0.8

Commodity contracts
 
Other assets
 
0.1

 
Other noncurrent liabilities
 
0.2

Swap contracts
 
Other current assets
 
2.8

 
Accrued expenses and other current liabilities
 

Total derivatives designated as hedging instruments(a)(b)
 
 
 
$
3.2

 
 
 
$
1.0

(a)
The Company has master netting agreements with its commodity hedge counterparties and accordingly has netted in its Consolidated Balance Sheets $0.4 million of its commodity contracts that are in a receivable position against its contracts in payable positions.
(b)
The Company has both commodity hedge and foreign currency swap agreements with two counterparties each. Amounts recorded as liabilities for the Company’s commodity contracts are payable to both counterparties, and amounts recorded as assets for the Company’s foreign currency swap agreements are receivable from both counterparties. 

13.
Fair Value Measurements:

The Company’s financial instruments are measured and reported at their estimated fair values. Fair value is the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction. When available, the Company uses quoted prices in active markets to determine the fair values for its financial instruments (Level 1 inputs) or, absent quoted market prices, observable market-corroborated inputs over the term of the financial instruments (Level 2 inputs). The Company does not have any unobservable inputs that are not corroborated by market inputs (Level 3 inputs).
 
The Company holds marketable securities associated with its defined contribution and pre-tax savings plans, which are valued based on readily available quoted market prices. The Company utilizes derivative instruments to manage its risk of changes in natural gas prices and its risk of changes in foreign currency exchange rates (see Note 12). The fair values of the natural gas and foreign currency derivative instruments are determined using market data of forward prices for all of the Company’s contracts. 

The estimated fair values for each type of instrument are presented below (in millions):
 
March 31,
2020
 
Level One
 
Level Two
 
Level Three
Asset Class:
 
 
 
 
 
 
 
Mutual fund investments in a non-qualified savings plan(a)
$
1.3

 
$
1.3

 
$

 
$

Derivatives – foreign currency contracts, net
1.7

 

 
1.7

 

Total Assets
$
3.0

 
$
1.3

 
$
1.7

 
$

Liability Class:
 

 
 

 
 

 
 

Liabilities related to non-qualified savings plan
$
(1.3
)
 
$
(1.3
)
 
$

 
$

Derivatives – natural gas instruments, net
(0.7
)
 

 
(0.7
)
 

Total Liabilities
$
(2.0
)
 
$
(1.3
)
 
$
(0.7
)
 
$

(a)
Includes mutual fund investments of approximately 30% in common stock of large-cap U.S. companies, 10% in common stock of small to mid-cap U.S. companies, 5% in international companies, 20% in bond funds, 10% in short-term investments and 25% in blended funds.


21


 
December 31,
2019
 
 
Level One
 
 
Level Two
 
 
Level Three
Asset Class:
 
 
 
 
 
 
 
Mutual fund investments in a non-qualified savings plan(a)
$
1.4

 
$
1.4

 
$

 
$

Derivatives – foreign currency contracts, net
2.8

 

 
2.8

 

Total Assets
$
4.2

 
$
1.4

 
$
2.8

 
$

Liability Class:
 

 
 

 
 

 
 

Liabilities related to non-qualified savings plan
$
(1.4
)
 
$
(1.4
)
 
$

 
$

Derivatives – natural gas instruments, net
(0.6
)
 

 
(0.6
)
 

Total Liabilities
$
(2.0
)
 
$
(1.4
)
 
$
(0.6
)
 
$

(a)
Includes mutual fund investments of approximately 30% in the common stock of large-cap U.S. companies, 15% in the common stock of small to mid-cap U.S. companies, 5% in the common stock of international companies, 10% in bond funds, 20% in short-term investments and 20% in blended funds.

Cash and cash equivalents, accounts receivable (net of allowance for bad debts) and payables are carried at cost, which approximates fair value due to their liquid and short-term nature. The Company’s investments related to its nonqualified savings plan of $1.3 million and $1.4 million at March 31, 2020 and December 31, 2019, respectively, are stated at fair value based on quoted market prices. As of March 31, 2020 and December 31, 2019, the estimated amount a third party would pay for the Company’s fixed-rate 4.875% Senior Notes due July 2024, based on available trading information (Level 2), totaled $235.0 million and $249.1 million, respectively, compared with the aggregate principal amount at maturity of $250.0 million. As of March 31, 2020 and December 31, 2019, the estimated amount a third party would pay for the Company’s fixed-rate 6.75% Senior Notes due December 2027, based on available trading information (Level 2), totaled $451.4 million and $530.6 million, respectively, compared with the aggregate principal amount at maturity of $500.0 million. The estimated amount a third party would pay at March 31, 2020 and December 31, 2019 for the amounts outstanding under the Company’s term loans and revolving credit facility, based upon available bid information received from the Company’s lender (Level 2), totaled $451.3 million and $552.8 million, respectively, compared with the aggregate principal balance of $456.5 million and $560.0 million, respectively. The Brazilian loans have floating rates and their fair value approximates their carrying value.

14.
Earnings per Share:
 
The Company calculates earnings per share using the two-class method. The two-class method requires allocating the Company’s net earnings to both common shares and participating securities. The following table sets forth the computation of basic and diluted earnings per common share (in millions, except for share and per-share data):
 
Three Months Ended
March 31,
 
2020
 
2019
Numerator:
 
 
 
Net earnings
$
27.6

 
$
7.6

Less: net earnings allocated to participating securities(a)
(0.5
)
 
(0.2
)
Net earnings available to common shareholders
$
27.1

 
$
7.4

 
 
 
 
Denominator (in thousands):
 

 
 

Weighted-average common shares outstanding, shares for basic earnings per share
33,892

 
33,874

Weighted-average awards outstanding(b)

 

Shares for diluted earnings per share
33,892

 
33,874

Net earnings per common share, basic
$
0.80

 
$
0.22

Net earnings per common share, diluted
$
0.80

 
$
0.22

(a)
Weighted participating securities include RSUs and PSUs that receive non-forfeitable dividends and consist of 412,000 and 233,000 weighted participating securities for the three months ended March 31, 2020 and 2019, respectively.
(b)
For the calculation of diluted net earnings per share, the Company uses the more dilutive of either the treasury stock method or the two-class method to determine the weighted-average number of outstanding common shares. In addition, the Company had 1,266,000 and 788,000 weighted-average equity awards outstanding for the three months ended March 31, 2020 and 2019, respectively.


22


Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations
 
All statements, other than statements of historical fact, contained in this Quarterly Report on Form 10-Q constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.
 
Forward-looking statements relate to future events or our future financial performance, and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements include, but are not limited to, the following: risks related to the coronavirus (“COVID-19”) pandemic; our mining and industrial operations; geological conditions; dependency on a limited number of key production and distribution facilities and critical equipment; weather conditions; strikes, other forms of work stoppage or slowdown or other union activities; the inability to fund necessary capital expenditures or successfully complete capital projects; supply constraints or price increases for energy and raw materials used in our production processes; our indebtedness and inability to pay our indebtedness; restrictions in our debt agreements that may limit our ability to operate our business or require accelerated debt payments; tax liabilities; financial assurance requirements; the inability of our customers to access credit or a default by our customers of trade credit extended by us or financing we have guaranteed; our payment of any dividends; the impact of competition on the sales of our products; risks associated with our international operations and sales; the impact of anticipated changes in plant nutrition product prices and customer application rates; conditions in the agricultural sector and supply and demand imbalances for competing plant nutrition products; increasing costs or a lack of availability of transportation services; the seasonal demand for our products; our rights and governmental authorizations to mine and operate our properties; compliance with foreign and United States (“U.S.”) laws and regulations related to import and export requirements and anti-corruption laws; compliance with environmental, health and safety laws and regulations; environmental liabilities; misappropriation or infringement claims relating to intellectual property; product liability claims and product recalls; inability to obtain required product registrations or increased regulatory requirements; changes in industry standards and regulatory requirements; our ability to successfully implement our strategies, including the strategic review of our Plant Nutrition South America business; the loss of key personnel; a compromise of our computer systems, information technology or operations technology or the inability to protect confidential or proprietary data; our ability to expand our business through acquisitions, integrate acquired businesses and realize anticipated benefits from acquisitions; climate change; domestic and international general business and economic conditions; and other risks referenced from time to time in this report and our other filings with the Securities and Exchange Commission (the “SEC”), including the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2019.
 
In some cases, you can identify forward-looking statements by terminology such as “may,” “might,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” the negative of these terms or other comparable terminology. Forward-looking statements include without limitation statements about our the impact of COVID-19 pandemic on us; our outlook, including expected sales volumes; our strategic evaluation of our Plant Nutrition South America business; working capital requirements; our reinvestment of foreign earnings outside the U.S.; our ability to optimize cash accessibility, minimize tax expense and meet debt service requirements; future tax payments and tax refunds; outcomes of matters with taxing authorities; the effects of currency fluctuations and inflation; and the seasonality of our business. These forward-looking statements are only predictions. Actual events or results may differ materially.
 
Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We undertake no duty to update any of the forward-looking statements after the date hereof or to reflect the occurrence of unanticipated events.
 
Unless the context requires otherwise, references to the “Company,” “Compass Minerals,” “our,” “us” and “we” refer to Compass Minerals International, Inc. (“CMI,” the parent holding company) and its consolidated subsidiaries. Except where otherwise noted, references to North America include only the continental U.S. and Canada, and references to the United Kingdom (the “U.K.”) include only England, Scotland and Wales. Except where otherwise noted, all references to tons refer to “short tons” and all amounts are in U.S. dollars. One short ton equals 2,000 pounds. Compass Minerals, Protassium+ and Wolf Trax, and combinations thereof, are trademarks of CMI or its subsidiaries in the U.S. and other countries. 
 
COVID-19 Pandemic

The global spread of the COVID-19 pandemic in recent months has negatively impacted the global economy, disrupted global supply chains and created significant volatility and disruption of financial markets. As an essential business, we have continued producing and delivering products that support critical industries such as transportation, agriculture, chemical, food, pharmaceutical and animal nutrition. However, we have instituted several measures in response to the COVID-19 pandemic.

23


Employee welfare: Our management team has taken multiple actions to limit the exposure of employees to the spread of COVID-19, including instituting remote working where possible, adjusting shift schedules and crew sizes, restricting visitation to operational sites, prohibiting all business-related commercial air travel, and increasing sanitation of offices and common areas within our facilities.
Operations: Our manufacturing facilities in North America and Brazil remained in operation throughout the first quarter. Operations at our U.K. salt mine were idled near the end of March due to the very mild winter weather experienced in that market, along with U.K. government guidance on COVID-19 preventative measures.
Supply chain and logistics: To date, we have experienced no material supply chain or logistics issues. We continue to evaluate potential supply chain and logistics impacts, proactively increase inventory levels of critical sourced inputs and identify secondary suppliers where possible. Both our operations and our logistics partners are deemed “essential” under current governmental guidance and we have worked to ensure we understand and comply with their safety precautions to limit potential disruptions.

The ultimate impact that COVID-19 will have on our 2020 results is unknown at this time. However, we have identified several potential impacts on our business, which include:
A protracted North American economic shutdown could lower bid volumes due to budgetary limitations or reduced traffic on the roadways.
Customer access to retailers in our North American markets could impact consumer and industrial product demand.
Potential reduced demand in our specialty crop markets in North America. As a result, we have lowered our 2020 Plant Nutrition North America volume guidance to 340,000 to 365,000 tons.
A significant decline in global demand of crops that use our Plant Nutrition South America products could reduce demand in this segment.

For more information, see “Part II–Item 1A–Risk Factors.”

Critical Accounting Estimates

Preparation of our consolidated financial statements in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Management believes the most complex and sensitive judgments result primarily from the need to make estimates about matters that are inherently uncertain. Management’s Discussion and Analysis and Note 2 to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2019 describe the significant accounting estimates and policies used in preparation of our consolidated financial statements. For a further description of our critical accounting policies, see Note 1 to our Consolidated Financial Statements included in this Quarterly Report on Form 10-Q. Actual results in these areas could differ from management’s estimates.

Company Overview

Compass Minerals is a leading producer of essential minerals, including salt, sulfate of potash (“SOP”) specialty fertilizer and magnesium chloride. As of March 31, 2020, we operated 21 production and packaging facilities, including:
The largest rock salt mine in the world in Goderich, Ontario, Canada;
The largest dedicated rock salt mine in the U.K. in Winsford, Cheshire;
A solar evaporation facility located in Ogden, Utah, which is both the largest SOP production site and the largest solar salt production site in the Western Hemisphere;
Several mechanical evaporation facilities producing consumer and industrial salt; and
Several facilities producing essential agricultural nutrients and specialty chemicals in Brazil.

Our salt business provides highway deicing salt to customers in North America and the U.K. as well as consumer deicing and water conditioning products, ingredients used in consumer and commercial food preparation, and other salt-based products for consumer, agricultural and industrial applications in North America. In the U.K., we operate a records management business utilizing excavated areas of our Winsford salt mine with one other surface location in London, England.

Our plant nutrition business produces and markets specialty plant nutrition products worldwide to distributors and retailers of crop inputs, as well as growers. Our principal plant nutrition product in our Plant Nutrition North America segment is SOP, which we market under the trade name Protassium+. We also sell various secondary nutrients as well as premium micronutrient products under our Wolf Trax brand.


24


Our Plant Nutrition South America segment operates two primary businesses in Brazil—agricultural productivity, which manufactures and distributes a broad offering of specialty plant nutrition solution-based products; and chemical solutions, which manufactures and markets specialty chemicals, primarily for the water treatment industry and for use in other industrial processes.

Consolidated Results of Operations

The following is a summary of our consolidated results of operations for the three months ended March 31, 2019 and 2020, respectively. The following discussion should be read in conjunction with the information contained in our consolidated financial statements and the notes thereto included in this Quarterly Report on Form 10-Q.

THREE MONTHS ENDED MARCH 31
CHART-D52DF64AFB8853DAA7A.JPG CHART-9364F58739AA5F5D8F4.JPG
CHART-FFA455964F7351F7AFB.JPG CHART-9D158FC0D9C257CD9FF.JPG
* Refer to “—Sensitivity Analysis Related to EBITDA and Adjusted EBITDA” for a reconciliation to the most directly comparable U.S. GAAP financial measure and the reasons we use this non-GAAP measure.

COMMENTARY: THREE MONTHS ENDED MARCH 31, 2019 AND 2020

Total sales increased 3%, or $10.2 million, due to increases in both plant nutrition businesses, which were partially offset by a decrease in Salt sales.
Operating earnings increased 33%, or $11.0 million, due to increases in all businesses.
Earnings before interest, taxes, depreciation and amortization (“EBITDA”)* adjusted for items management believes are not indicative of our ongoing operating performance (“Adjusted EBITDA”)* increased 15%, or $10.4 million.
Diluted net earnings per share increased 264%, or $0.58.




25


THREE MONTHS ENDED MARCH 31
CHART-05B24906A6A854E2B51.JPG CHART-164FD37487A85DFA87F.JPG
COMMENTARY: THREE MONTHS ENDED MARCH 31, 2019 AND 2020

Gross Profit: Increased 20%, or $14.7 million; Gross Margin increased by 3 percentage points
Salt segment gross profit increased $5.4 million primarily due to higher average sales prices, which were partially offset by higher per-unit product cost due to costs resulting from upgrades to our mining equipment and sales of higher cost purchased salt.
The gross profit of the plant nutrition business, on a combined basis, increased $9.2 million. Plant Nutrition North America segment gross profit increased $5.8 million primarily due to higher sales volumes, lower production costs and lower per-unit shipping and handling costs, which was partially offset by lower average sales prices. Plant Nutrition South America segment gross profit increased $3.4 million primarily due to higher sales volumes and lower per unit product costs, which were partially offset by lower average sales prices.

OTHER EXPENSES AND INCOME

COMMENTARY: THREE MONTHS ENDED MARCH 31, 2019 AND 2020

SG&A: Increased $3.7 million; increased 0.6 percentage points as a percentage of sales from 9.8% to 10.4%
The increase in SG&A expense was primarily due to higher corporate salaries and wages and incentive compensation in the current year compared to the prior year due, in part, to severance expense incurred in the current period.

Interest Expense: Increased $2.8 million to $19.0 million
The increase was primarily due to an increase in interest rates due to the refinancing of our debt in the fourth quarter of 2019.

(Gain) Loss on Foreign Exchange: Improved $19.3 million from an expense of $5.0 million to income of $14.3 million
We realized foreign exchange gains of $14.3 million in the first quarter of 2020 compared to a loss of $5.0 million in the first quarter of 2019 due primarily to changes in translating our intercompany loans from Canadian dollars to U.S. dollars.

Other Expense (Income), Net: Decreased $0.7 million from income of $0.6 million to an expense of $0.1 million
The decrease in other expense (income) is primarily due to losses incurred in the current period related to our non-qualified plan for certain executives.

Income Tax Expense: Increased $6.8 million from $4.9 million to $11.7 million
The increase in income tax expense was primarily due to higher pretax income in the first quarter of 2020 versus the first quarter of 2019 offset by the discrete tax expense items in the first quarter of 2019.
Our income tax provision in both periods differs from the U.S. statutory rate primarily due to U.S. statutory depletion, state income taxes, global intangible low-taxed income, foreign income, mining and withholding taxes and interest expense recognition differences for tax and financial reporting purposes.
Our effective tax rate declined from 39% in the first quarter of 2019 to 30% in the first quarter of 2020 primarily due to the impact of discrete tax items in the first quarter of 2019.


26


Operating Segment Performance
The following financial results represent consolidated financial information with respect to sales from our Salt, Plant Nutrition North America and Plant Nutrition South America segments. The results of operations of the consolidated records management business and other incidental revenues include sales of $2.7 million and $2.4 million for the first quarter of 2020 and 2019, respectively. These revenues are not material to our consolidated financial results and are not included in the following operating segment financial data.

Salt

THREE MONTHS ENDED MARCH 31

CHART-5F9FF8CF7E9C57DFA42.JPG
 
1Q 2020
 
1Q 2019
Salt Sales (in millions)
$
287.8

 
$
306.4

Salt Operating Earnings (in millions)
$
56.9

 
$
52.3

Salt Sales Volumes (thousands of tons)
 
 
 
Highway deicing
3,104

 
3,543

Consumer and industrial
469

 
551

Total tons sold
3,573

 
4,094

Average Salt Sales Price (per ton)
 
 
 
Highway deicing
$
69.30

 
$
61.73

Consumer and industrial
$
154.84

 
$
159.23

Combined
$
80.53

 
$
74.84


COMMENTARY: THREE MONTHS ENDED MARCH 31, 2019 AND 2020

Salt sales decreased 6%, or $18.6 million, primarily due to lower Salt sales volumes, which were partially offset by higher highway deicing average sales prices.
Salt average sales prices increased 8% and contributed $21.4 million to sales due to higher highway deicing prices.
Highway deicing average sales prices increased 12% due to higher North American highway deicing contract prices for the 2019-2020 winter season. Consumer and industrial average sales prices decreased 3% due to sales mix.
Salt sales volumes decreased 13%, or 521,000 tons, and unfavorably impacted sales by $40.0 million. Highway deicing sales volumes decreased 12% primarily as result of milder winter weather in the first quarter of 2020 in North America and the U.K. Consumer and industrial sales volumes also decreased 15% due to lower sales of deicing products.
Salt operating earnings increased 9%, or $4.6 million, due to higher highway deicing prices, which were partially offset by higher per-unit cost primarily due to lower production volumes in the U.K., costs related to upgrading our mining equipment at our Goderich mine and increased sales of higher cost purchased salt.

27


Plant Nutrition North America

THREE MONTHS ENDED MARCH 31

CHART-8843AE448B4155A9BD2.JPG
 
1Q 2020
 
1Q 2019
Plant Nutrition North America Sales (in millions)
$
60.6

 
$
37.2

Plant Nutrition North America Operating Earnings (Loss) (in millions)
$
5.2

 
$
(1.6
)
Plant Nutrition North America Sales Volumes (thousands of tons)
96

 
57

Plant Nutrition North America Average Sales Price (per ton)
$
632

 
$
656


COMMENTARY: THREE MONTHS ENDED MARCH 31, 2019 AND 2020

Plant Nutrition North America sales increased 63%, or $23.4 million due to higher sales volumes, which was partially offset by lower average sales prices.
Plant Nutrition North America sales volumes increased 68%, or 39,000 tons, which resulted in a $25.6 million increase in sales. Sales volume in the first quarter of 2019 were lower due to the cold and wet weather experienced in our key markets.
Plant Nutrition North America average sales prices decreased 4%, providing a $2.2 million offset to the increase in sales.
Plant Nutrition North America operating earnings increased $6.8 million to $5.2 million due to higher sales volumes, lower per-unit product and shipping and handling costs and lower selling, general and administrative expenses, which were partially offset by lower average sales prices.

Plant Nutrition South America

THREE MONTHS ENDED MARCH 31

CHART-62C10EDB169E595CAAB.JPG

28


 
1Q 2020
 
1Q 2019
Plant Nutrition South America Sales (in millions)
$
62.8

 
$
57.7

Plant Nutrition South America Operating Earnings (Loss) (in millions)
$
0.3

 
$
(2.6
)
Plant Nutrition South America Sales Volumes (thousands of tons)
 
 
 
Agricultural productivity
68

 
52

Chemical solutions
90

 
82

Total tons sold
158

 
134

Average Plant Nutrition South America Sales Price (per ton)
 
 
 
Agricultural productivity
$
602

 
$
681

Chemical solutions
$
242

 
$
275

Combined
$
397

 
$
431


COMMENTARY: THREE MONTHS ENDED MARCH 31, 2019 AND 2020

Plant Nutrition South America sales increased 9%, or $5.1 million, due to higher sales volumes, which were partially offset by lower average sales prices due to a 14% unfavorable weighted average change in the Brazilian reais versus the U.S. dollar from the prior year.
Plant Nutrition South America sales volumes increased 18%, or 24,000 tons, which accounted for $13.4 million of the increase in Plant Nutrition South America sales. Agricultural productivity sales volumes increased 31% due primarily to improvements in farmer economics and affordability of fertilizer products due to foreign exchange and barter rates. Chemical solutions sales volumes increased 10% due to higher sales of water treatment products.
An 8% decrease in Plant Nutrition South America average sales price reduced sales by $8.3 million. The decrease in average sales price was due to a 12% decrease in both chemical solutions and agricultural productivity prices as a result of the weighted average change in the Brazilian reais versus the U.S. dollar. In local currency, a stronger mix of agricultural productivity sales resulted in a 5% increase in average sales prices.
Plant Nutrition South America operating earnings increased $2.9 million to $0.3 million due to higher sales volumes and improved margins, partially offset by a weaker reais.

2020 Full-Year Outlook

As a result of the mild first quarter winter weather, we expect Salt sales volumes for 2020 to range from 10.7 million tons to 11.1 million tons.
Plant Nutrition North America sales volumes for 2020 are expected to range from 340,000 tons to 365,000 tons.
We expect 2020 Plant Nutrition South America, sales volumes to range from 800,000 tons to 900,000 tons.
In light of the COVID-19 pandemic and its impact on the global economy and capital markets, we have temporarily suspended our strategic review of our Plant Nutrition South America business. For more information about the impact of the COVID-19 pandemic on the Company, see “–COVID-19 Pandemic” and “Part II–Item 1A–Risk Factors.”

Liquidity and Capital Resources
 
Historically, our cash flows from operating activities have generally been adequate to fund our basic operating requirements and ongoing debt service. We have also used cash generated from operations to fund capital expenditures which strengthen our operational position, pay dividends, fund smaller acquisitions and repay our debt. To a certain extent, our ability to meet our short- and long-term liquidity and capital needs is subject to general economic, financial, competitive, legislative, regulatory and weather conditions, effects of climate change, geological variations in our mine deposits and other factors that are beyond our control. Historically, our working capital requirements have been the highest in the fourth quarter and lowest in the second quarter. When needed, we may fund short-term working capital requirements by accessing our $300 million revolving credit facility.

We have been able to manage our cash flows generated and used across Compass Minerals to permanently reinvest earnings in our foreign jurisdictions or efficiently repatriate those funds to the U.S. As of March 31, 2020, we had $33.9 million of cash and cash equivalents (in our Consolidated Balance Sheets) that were either held directly or indirectly by foreign subsidiaries. During the fourth quarter of 2018, we revised our permanently reinvested assertion to indicate that we expect to repatriate approximately $150 million of unremitted foreign earnings on which we have recorded a $4.8 million deferred tax liability as of March 31, 2020 for foreign withholding tax and state income tax. Due to our ability to generate adequate levels of domestic cash flow on an annual basis, it is our current intention to continue to reinvest all remaining undistributed earnings of our foreign subsidiaries indefinitely. We review our tax circumstances on a regular basis with the intent of optimizing cash accessibility and minimizing tax expense.

29


In addition, the amount of permanently reinvested earnings is influenced by, among other things, the profits generated by our foreign subsidiaries and the amount of investment in those same subsidiaries. The profits generated by our domestic and foreign subsidiaries are impacted by the transfer price charged on the transfer of our products between them. As discussed in Note 7 to our Consolidated Financial Statements, our calculated transfer price on certain products between one of our foreign subsidiaries and a domestic subsidiary has been challenged by Canadian federal and provincial governments. In the fourth quarter of 2017, we reached a federal settlement agreement with Canadian and U.S. tax authorities related to our transfer pricing issues for our 2007-2012 tax years. The recording of this settlement resulted in increased sales for our Canadian subsidiary of $85.7 million and increased offsetting expenses for our US subsidiary in 2017 causing a domestic loss and significant foreign income. During 2018, in accordance with the settlement agreement, our U.S. subsidiary made intercompany cash payments of $85.7 million to our Canadian subsidiary and tax payments to Canadian taxing authorities of $17.5 million. The remaining liability was satisfied in 2019 with tax payments of $5.3 million. . Corresponding tax refunds of $21.4 million were received in 2019 from U.S. taxing authorities, with the remaining refund of approximately $1.6 million expected in 2020. Additionally during the fourth quarter of 2018, we reached a federal settlement agreement with Canadian and U.S. tax authorities on transfer pricing and management fees as part of an advanced pricing agreement that covers tax years 2013-2021. The recording of this settlement in 2018 resulted in increased sales for our Canadian subsidiary of $106.1 million and offsetting expenses for our US subsidiary causing a domestic loss and significant foreign income in 2018. During the second quarter of 2019, in accordance with the settlement agreement, our U.S. subsidiary made intercompany cash payments of $106.1 million to our Canadian subsidiary and tax payments to Canadian taxing authorities of $29.9 million with the remaining $1.3 million of tax payments to be paid during 2020. Corresponding tax refunds of $59.2 million have been received as of March 31, 2020 from U.S. taxing authorities, of which $55 million was received during the first quarter of 2020, with the remaining $2.4 million expected in 2020. There are ongoing challenges by Canadian provincial taxing authorities regarding our transfer prices of certain products. The final resolution of these challenges may not occur for several years. We currently expect the outcome of these matters will not have a material impact on our results of operations. However, it is possible the resolution could materially impact the amount of earnings attributable to our domestic and foreign subsidiaries, which could impact the amount of permanently reinvested foreign earnings as well as future cash flows from our domestic operations. See Note 7 to our Consolidated Financial Statements for a discussion regarding our Canadian tax reassessments and settlement.

A portion of our loans in Brazil are denominated in U.S. dollars. We have entered into a foreign currency agreement whereby we agreed to swap interest and principal payments on the loans denominated in U.S. dollars for principal and interest payments denominated in Brazilian reais, the functional currency of our Brazil subsidiary. See Note 12 to our Consolidated Financial Statements for a discussion of our foreign currency agreement.

Cash and cash equivalents as of March 31, 2020 of $109.8 million, increased $75.1 million from December 31, 2019. We generated $228.6 million of operating cash flows in the first three months of 2020. In the first three months of 2020, we used cash on hand and cash flows from operations to pay $97.7 million of net long-term debt, to fund capital expenditures of $25.3 million and pay dividends on our common stock of $24.8 million.

As of March 31, 2020, we had $1.31 billion of indebtedness, consisting of $250.0 million outstanding under our 4.875% Senior Notes due 2024, $500.0 million outstanding under our 6.75% Senior Notes due 2027, $456.5 million of borrowings outstanding under our senior secured credit facilities (consisting of term loans and a revolving credit facility), including $59.0 million borrowed against our revolving credit facility, and $101.3 million of Brazilian debt (see Note 8 to our Consolidated Financial Statements for more detail regarding our debt). We had $10.5 million of outstanding letters of credit as of March 31, 2020, which reduced our revolving credit facility borrowing availability to $230.5 million.
 
Our debt service obligations could, under certain circumstances, materially affect our financial condition and impair our ability to operate our business or pursue our business strategies. As a holding company, CMI’s investments in its operating subsidiaries constitute substantially all of its assets. Consequently, our subsidiaries conduct substantially all of our consolidated operating activities and own substantially all of our operating assets. The principal source of the cash needed to pay our obligations is the cash generated from our subsidiaries’ operations and their borrowings. Our subsidiaries are not obligated to make funds available to CMI. Furthermore, we must remain in compliance with the terms of our credit agreement governing our term loans and revolving credit facility, including the total leverage ratio and interest coverage ratio, in order to make payments on our debt or pay dividends to our stockholders. We must also comply with the terms of our indenture governing our senior notes. Although we are in compliance with our debt covenants as of March 31, 2020, we can make no assurance that we will remain in compliance with these ratios nor can we make any assurance that the agreements governing the current and future indebtedness of our subsidiaries will permit our subsidiaries to provide us with sufficient dividends, distributions or loans to fund scheduled interest payments on our debt when due. If we consummate an additional acquisition, our debt service requirements could increase. Furthermore, we may need to refinance all or a portion of our indebtedness on or before maturity; however, we cannot provide assurance that we will be able to refinance any of our indebtedness on commercially reasonable terms or at all.
 

30


The table below provides a summary of our cash flows by category:
THREE MONTHS ENDED MARCH 31, 2020
THREE MONTHS ENDED MARCH 31, 2019
Operating Activities:
» Net earnings were $27.6 million.
» Net earnings were $7.6 million.
» Non-cash depreciation and amortization expense was $33.1 million.
» Non-cash depreciation and amortization expense was $35.0 million.
» Working capital items were a source of operating cash flows of $171.7 million.
» Working capital items were a source of operating cash flows of $77.5 million.
Investing Activities:
» Net cash flows used by investing activities included $25.3 million of capital expenditures.
» Net cash flows used by investing activities included $21.5 million of capital expenditures.
Financing Activities:
» Net cash flows used by financing activities included the payment of dividends of $24.8 million.

» In addition, we had net payments on our debt $97.7 million.
» Net cash flows used by financing activities included the payment of dividends of $24.6 million.

» In addition, we had net payments on our debt of $64.9 million.

Other Matters

See Notes 7 and 9 to our Consolidated Financial Statements for a discussion regarding labor, environmental and litigation matters.

Sensitivity Analysis Related to EBITDA and Adjusted EBITDA
 
Management uses a variety of measures to evaluate our performance. While our consolidated financial statements, taken as a whole, provide an understanding of our overall results of operations, financial condition and cash flows, we analyze components of the consolidated financial statements to identify certain trends and evaluate specific performance areas. In addition to using U.S. GAAP financial measures, such as gross profit, net earnings and cash flows generated by operating activities, management uses EBITDA and Adjusted EBITDA. Both EBITDA and Adjusted EBITDA are non-GAAP financial measures used to evaluate the operating performance of our core business operations, because our resource allocation, financing methods, cost of capital and income tax positions are managed at a corporate level apart from the activities of the operating segments and our operating facilities are located in different taxing jurisdictions, which can cause considerable variation in net earnings. We also use these measures to assess our operating performance and return on capital, and to evaluate potential acquisitions or other capital projects. These measures are not calculated under U.S. GAAP and should not be considered in isolation or as a substitute for net earnings, operating earnings, cash flows or other financial data prepared in accordance with U.S. GAAP or as a measure of our overall profitability or liquidity. EBITDA and Adjusted EBITDA exclude interest expense, income taxes and depreciation and amortization, each of which are an essential element of our cost structure and cannot be eliminated. Furthermore, Adjusted EBITDA excludes other cash and non-cash items including stock-based compensation, (gain) loss on foreign exchange and other expense (income). Our borrowings are a significant component of our capital structure and interest expense is a continuing cost of debt. We are also required to pay income taxes, a required and ongoing consequence of our operations. We have a significant investment in capital assets and depreciation and amortization reflect the utilization of those assets in order to generate revenues. Consequently, any measure that excludes these elements has material limitations. While EBITDA and Adjusted EBITDA are frequently used as measures of operating performance, these terms are not necessarily comparable to similarly titled measures of other companies due to the potential inconsistencies in the method of calculation. 


31


The calculation of EBITDA and Adjusted EBITDA as used by management is set forth in the table below (in millions):
 
Three Months Ended
March 31,
 
2020
 
2019
Net earnings
$
27.6

 
$
7.6

Interest expense
19.0

 
16.2

Income tax expense
11.7

 
4.9

Depreciation, depletion and amortization
33.1

 
35.0

EBITDA
91.4

 
63.7

Adjustments to EBITDA:
 
 
 
  Stock-based compensation - non cash
2.4

 
1.1

  (Gain) loss on foreign exchange
(14.3
)
 
5.0

  Other expense (income), net
0.1

 
(0.6
)
Adjusted EBITDA
$
79.6

 
$
69.2


Recent Accounting Pronouncements
 
See Note 1 to our Consolidated Financial Statements for a discussion of recent accounting pronouncements.

Effects of Currency Fluctuations
 
Our operations outside of the U.S. are conducted primarily in Canada, Brazil and the U.K. Therefore, our results of operations are subject to both currency transaction risk and currency translation risk. We incur currency transaction risk whenever we or one of our subsidiaries enters into either a purchase or sales transaction using a currency other than the local currency of the transacting entity. With respect to currency translation risk, our financial condition and results of operations are measured and recorded in the relevant local currency and then translated into U.S. dollars for inclusion in our consolidated financial statements. Exchange rates between these currencies and the U.S. dollar have fluctuated significantly from time to time and may do so in the future. The majority of revenues and costs are denominated in U.S. dollars, with Canadian dollars, Brazilian reais and British pounds sterling also being significant. Significant changes in the value of the Canadian dollar, Brazilian reais or British pound sterling relative to the U.S. dollar could have a material effect on our financial condition.

Although inflation has not had a significant impact on our operations, our efforts to recover cost increases due to inflation may be hampered as a result of the competitive industries and countries in which we operate.

Seasonality

We experience a substantial amount of seasonality in our sales. Our sales of our salt deicing products are seasonal. Consequently, our Salt sales and operating income are generally higher in the first and fourth quarters and lower during the second and third quarters of each year. In particular, sales of highway and consumer deicing salt and magnesium chloride products vary based on the severity of the winter conditions in areas where the product is used. Following industry practice in North America, we seek to stockpile sufficient quantities of deicing salt in the second, third and fourth quarters to meet the estimated requirements for the winter season.

Our plant nutrition business is also seasonal. The strongest demand for our Plant Nutrition South America products in Brazil typically occurs during the spring planting season. As a result, we and our customers generally build inventories during the low demand periods of the year to ensure timely product availability during the peak sales season. The seasonality of this demand results in our sales volumes and net sales for our Plant Nutrition South America segment usually being the highest during the third and fourth quarters of each year (as the spring planting season begins in September in Brazil).


32


Item 3.    Quantitative and Qualitative Disclosures About Market Risk

Our business is subject to various types of market risks that include interest rate risk, foreign currency exchange rate risk and commodity pricing risk. Management has taken actions to mitigate our exposure to commodity pricing and foreign currency exchange rate risk by entering into natural gas derivative instruments and foreign currency contracts. We may take further actions to mitigate our exposure to interest rates, exchange rates and changes in the cost of transporting our products due to variations in our contracted carriers’ cost of fuel, which is typically diesel fuel. However, there can be no assurance that our hedging activities will eliminate or substantially reduce these risks. We do not enter into any financial instrument arrangements for speculative purposes. Our market risk exposure related to these items has not changed materially since December 31, 2019.

Item 4.    Controls and Procedures
 
Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) was performed under the supervision and with the participation of the Company’s management, including the Chief Executive Officer and Chief Financial Officer. Based on that evaluation, the Company’s Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective as of March 31, 2020 to ensure that information required to be disclosed in the reports it files and submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

For this purpose, disclosure controls and procedures include controls and procedures designed to ensure that information that is required to be disclosed under the Exchange Act is accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There has been no change in the Company’s internal control over financial reporting during the most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

33


PART II. OTHER INFORMATION
 

Item 1.    Legal Proceedings
 
We are involved in the legal proceedings described in Note 7 and Note 9 to our Consolidated Financial Statements and, from time to time, various routine legal proceedings and claims arising from the ordinary course of our business. These primarily involve tax assessments, disputes with former employees and contract labor, commercial claims, product liability claims, personal injury claims and workers’ compensation claims. Management cannot predict the outcome of legal proceedings and claims with certainty. Nevertheless, management believes that the outcome of legal proceedings and claims, which are pending or known to be threatened, even if determined adversely, will not, either individually or in the aggregate, have a material adverse effect on our results of operations, cash flows or financial condition. There have been no material developments since December 31, 2019 with respect to our legal proceedings, except as described in Note 7 and Note 9 to our Consolidated Financial Statements.

Item 1A.    Risk Factors

For a discussion of the risk factors applicable to Compass Minerals, please refer to Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019, as updated and supplemented by the discussion below related to the COVID-19 pandemic. 

The COVID-19 pandemic, or other outbreaks of infectious disease or similar public health threats, could materially and adversely affect our business, financial condition and results of operations.

The recent outbreak of COVID-19, and any other outbreaks of contagious diseases or other adverse public health developments in the United States or worldwide, could have a material adverse effect on our business, financial condition and results of operations. As an essential business, we have continued producing and delivering products that support critical industries such as transportation, agriculture, chemical, food, pharmaceutical and animal nutrition. However, COVID-19 has significantly impacted economic activity and markets worldwide in 2020, and it could negatively affect our business in a number of ways. These effects could include, but are not limited to:
Disruptions or restrictions on our employees’ ability to work effectively due to illness, travel bans, quarantines, shelter-in-place orders or other limitations could impact our business.
Temporary closures of our facilities or the facilities of our customers or suppliers could reduce demand for our products or affect our ability to timely meet our customer’s orders and negatively impact our supply chain. Compliance with new governmental regulations, such as social distancing regulations, could increase our operational costs. Our mining and manufacturing facilities in North America and Brazil remained in operation throughout the first quarter of 2020; however, operations at our U.K. salt mine were idled near the end of March 2020 due to the mild 2019-2020 winter weather experienced in that market, along with U.K. government guidance on COVID-19 preventative measures.
Our mining and manufacturing facilities rely on raw materials and components provided by our suppliers. If the ongoing quarantining or similar measures cause delays along our supply chain, we could experience a mining or manufacturing slow-down or seek to obtain alternate sources of supply, which may not be available or may be more expensive. Disruptions to our supply chain and business operations, or to our suppliers’ or customers’ supply chains and business operations, could include disruptions from the closure of supplier and manufacturer facilities, interruptions in the supply of raw materials and components, personnel absences, or restrictions on the shipment of our or our suppliers’ or customers’ products, any of which could have adverse ripple effects on our business.
Global health concerns, such as COVID-19, could result in social, economic, and labor instability in the countries and localities in which we or our suppliers and customers operate. Any of these uncertainties could have a material adverse effect on our business, financial condition or results of operations.
The failure of third parties on which we rely, including our suppliers, customers, contractors, commercial banks and external business partners, to meet their respective obligations to the Company, or significant disruptions in their ability to do so, which may be caused by their own financial or operational difficulties, could have an adverse impact on our business, financial condition or results of operations.
Remote work arrangements for our employees could strain our technology resources and introduce operational risks, including heightened cybersecurity risk. Remote working environments may be less secure and more susceptible to hacking attacks, including phishing and social engineering attempts that seek to exploit the COVID-19 pandemic. These risks could also impact the third parties on which we rely.
The COVID-19 pandemic has significantly increased economic and demand uncertainty and has led to disruption and volatility in the global credit and financial markets, which increases the cost of capital and adversely impacts access to capital for both the Company and our customers and suppliers. Disruption and volatility in the global and financial

34


markets or other factors may also cause adverse fluctuations in foreign currency exchange rates, particularly an increase in the value of the U.S. dollar against the Canadian dollar, the Brazilian reais or the U.K. pound sterling, which could negatively affect our business, financial condition and reported results of operations.

The impact of COVID-19 may also exacerbate other risks discussed in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019, any of which could have a material adverse effect on us. The extent to which the COVID-19 pandemic, or other outbreaks of disease or similar public health threats, materially and adversely impact our business, financial condition and results of operations is highly uncertain and will depend on future developments. Such developments may include the geographic spread and duration of the virus, the severity of the disease and the actions that may be taken by various governmental authorities and other third parties in response to the outbreak. In addition, how quickly, and to what extent, normal economic and operating conditions can resume cannot be predicted, and the resumption of normal business operations may be delayed or constrained by lingering effects on our suppliers, third-party service providers and customers.

Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds
 
(a)    None.

(b)    None.

(c)     Issuer Purchases of Equity Securities

The Company withheld 1,479 shares with a fair value of $0.1 million related to the vesting of RSUs during the first three months of 2020. The fair value of the shares were valued at the closing price at the vesting date and represent the employee tax withholding for the employee’s compensation. These shares are not considered common stock repurchases under the Company’s equity compensation plans.

Item 3.    Defaults Upon Senior Securities
 
None.
 
Item 4.    Mine Safety Disclosures
 
Information concerning mine safety violations or other regulatory matters required by Section 1503(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 104 of Regulation S-K is included in Exhibit 95 to this Quarterly Report on Form 10-Q.
 
Item 5.    Other Information
 
None.
 

35


Item 6.    Exhibits

Exhibit
No.
 
Exhibit Description
 
 
 
 
 
95*
 
101**
 
The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, formatted in Inline Extensible Business Reporting Language (iXBRL): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Comprehensive (Loss) Income, (iv) Consolidated Statements of Stockholders’ Equity, (v) Consolidated Statements of Cash Flows, and (vi) the Notes to the Consolidated Financial Statements.
104
 
Cover Page Interactive Data File (contained in Exhibit 101).
*    Filed herewith
**    Furnished herewith

36


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
COMPASS MINERALS INTERNATIONAL, INC.
 
 
 
 
 
Date: May 6, 2020
By:
/s/ James D. Standen
 
 
 
James D. Standen
 
 
 
Chief Financial Officer
 
 
 
(Principal Financial and Accounting Officer)
 


37
Exhibit 10.1

Final Release and Waiver of Claims
This Final Release and Waiver of Claims (the “Agreement”) is by and between Compass Minerals International, Inc. (the “Company”) and Angela Y. Jones (“You” or “Your”) (collectively, the “Parties”).

Whereas, You worked for the Company as Chief People Officer in Overland Park, Kansas; and
Whereas, the Company and You have agreed to conclude Your employment with the Company on the terms set forth herein as of February 19, 2020 (the “Termination Date”).
Now, therefore, the Parties agree as follows:
1.    Company Consideration. In exchange for the consideration You are providing under this Agreement, the Company (provided You timely sign and do not revoke this Agreement and this Agreement becomes effective) agrees to:
a.    provide You a lump sum severance payment equal to one (1) times Your annual base salary ($370,000.00) (less applicable deductions and withholdings), within 60 days after the Termination Date.
b.    provide You a lump sum payment of $240,500, representing Your annual cash bonus relating to 2020 (less applicable withholdings and deductions), within 60 days after the Termination Date.
c.    provide You a lump sum payment of $206,503, representing Your annual cash bonus relating to 2019 (less applicable withholdings and deductions), within 60 days after the Termination Date.
d.    pay the premiums due ($12,846.00 in aggregate) under the Consolidated Omnibus Budget Reconciliation Act (“COBRA”) to continue coverage under the Company’s health, vision and dental plans in effect as of the Termination Date, for You and Your dependents, if any, for 18 months immediately following the Termination Date, directly to the insurer/COBRA administrator on Your behalf; provided You and Your dependents, if any, were enrolled in such plans prior to the Termination Date and further provided You timely enroll for COBRA benefits.
e.    provide You a lump sum payment equal to the value of 7,247 shares of the Company’s stock underlying the restrictive stock units (“RSUs”) granted to You and that would have vested pro rata pursuant to Section 4(c)(i)(A) of the Company’s Executive Severance Plan effective as of January 1, 2019 (the “Severance Plan”), calculated based on the closing market price on the Termination Date, granted in exchange for cancelling such vested RSUs, to be paid in a lump sum payment (less applicable withholdings and deductions), within 60 days after the Termination Date.
f.    provide You with outplacement assistance through Lee Hecht Harrison; provided activation occurs by April 1, 2020.
g.    enter into the Consulting Agreement, attached to this Agreement as Exhibit A, entered into contemporaneously hereto.
2.    Your Consideration and Release. In exchange for the consideration the Company is providing under this Agreement, You agree as follows:



a.    You release and waive, to the maximum extent permitted by law, and without exception, any and all known, unknown, suspected, or unsuspected claims, demands, or causes of action (collectively, “claims”), arising at any time in the past up to and including the date You execute this Agreement, that You have or could have against the Company, as well as its past, present and future parents, subsidiaries, affiliates and all other related entities; its and their predecessors, successors and assigns; the past, present and future officers, directors, shareholders, trustees, members, employees, attorneys and agents of any of the previously listed entities; any benefits plan maintained by any of the previously listed entities at any time; and the past, present and future sponsors, insurers, trustees, fiduciaries and administrators of such benefit plans (collectively, “Affiliates”). The claims You release and waive include but are not limited to:
(1)    claims related to Your employment and the termination of Your employment with the Company or its Affiliates.
(2)    claims under any federal, state, or local constitution, statute, regulation, ordinance, or other legislative or administrative enactment (as amended), including but not limited to:
The Age Discrimination in Employment Act, The Older Workers Benefit Protection Act, Title VII of the Civil Rights Act of 1964, 42 U.S.C. §§ 1981-1988, the Civil Rights Act of 1991, the Equal Pay Act, the Pregnancy Discrimination Act, the Americans with Disabilities Act, the Rehabilitation Act, and the Genetic Information Nondiscrimination Act.
the Employee Retirement Income Security Act (except for any vested benefits under any tax qualified benefit plan).
the Family and Medical Leave Act.
the Fair Labor Standards Act.
the Sarbanes-Oxley Act.
the Occupational Safety and Health Act.
the Immigration Reform and Control Act.
the Worker Adjustment and Retraining Notification Act.
the Fair Credit Reporting Act.
the Consolidated Omnibus Budget Reconciliation Act (COBRA).
the National Labor Relations Act.
the Kansas Act Against Discrimination.
the Kansas Age Discrimination in Employment Act.
the Kansas Service Letter Statute.
the Kansas Workers’ Compensation Act.
Kansas state wage payment and work hour laws.

(3)    claims for, based on, or related to discrimination, harassment, or retaliation; retaliation for exercising any right or participating or engaging in any protected activity; fraud or misrepresentation; violation of any public policy; workers’ compensation; the payment of compensation, benefits, sick leave, paid time off, or vacation; any bonus, health, stock option, retirement, or benefit plan; tort; contract; and common law.
(4)    claims to recover costs, fees, or other expenses, including attorneys’ fees, incurred in any matter.

- 2 -


Note 1: You are not releasing any claims that You cannot release or waive by law, including but not limited to the right to file a charge with, or participate in an investigation conducted by, any appropriate federal, state or local government agency. Further, nothing in this Agreement should be construed to prohibit You from such filings or participation. You are, however, releasing and waiving Your right, and the right of anyone claiming on Your behalf, to any monetary recovery should any government agency (such as the Equal Employment Opportunity Commission (“EEOC”), National Labor Relations Board (“NLRB”), Occupational Safety and Health Administration (“OSHA”), Securities and Exchange Commission (“SEC”) or Department of Labor (“DOL”)) pursue any claims on Your behalf. Notwithstanding this Note 1, nothing contained in this Agreement shall impede Your ability to report possible federal securities violations to the SEC and other governmental agencies (i) without the Company’s approval and (ii) without having to forfeit or forego any resulting whistleblower awards.

Note 2: You warrant and represent that (1) You have been paid all compensation due and owing through the Effective Date, including minimum wage, overtime, commissions, and bonuses; (2) You have not suffered any workplace injury or illness; (3) You are not aware of any illegal or fraudulent conduct by or on behalf of the Company or its Affiliates; (4) You have not been denied any requested time off or leave of absence or experienced any retaliation for requesting time off or a leave of absence; and (5) You are not aware of any facts that would substantiate a claim that the Company, or any of its Affiliates, has violated Your rights or the rights of any other employee in any way or with regard to any law, including but not limited to the claims You released and waived in this Agreement.

Note 3: Nothing in this Section 2 is intended to limit or restrict Your right to enforce this Agreement.

b.    You shall reasonably cooperate with the Company and its Affiliates in any ongoing or future investigation or litigation as requested by the Company. The Company shall reimburse You for reasonable and necessary expenses associated with Your cooperation. This requirement does not limit Your right to file a charge with, or participate in, an investigation conducted by any appropriate federal, state or local government agency (such as the EEOC, NLRB, SEC, DOL or OSHA), nor does it require You to provide anything other than truthful information in good faith to the best of Your ability.
c.    You will not disparage in any way, or make negative comments of any sort, about the Company or its Affiliates, their employees, customers, or vendors, whether orally or in writing, and whether to a third party or to an employee of the Company or its Affiliates. The Company agrees to instruct its current executive officers (as listed in the annual report on Form 10-K to be filed with the SEC on or about February 26, 2020) to not disparage You in any way or make negative comments of any sort about You. This prohibition does not limit Your right to file a charge with, or participate in, an investigation conducted by any appropriate federal, state or local government agency (such as the EEOC, NLRB, SEC, DOL or OSHA), nor does it require You to provide anything other than truthful information in good faith to the best of Your ability.
d.    You agree that You will not, on Your own behalf or on behalf of any other person, file or initiate any civil complaint or suit against the Company or its Affiliates in any forum for any claims waived or released by this Agreement. If You violate this provision by filing such complaint or civil suit, and such filing is found to be a violation, the Company shall be entitled to recover and You

- 3 -


shall be liable for the Company’s reasonable attorneys’ fees, expenses and costs of defending such litigation.
e.    You agree that, as of the Termination Date, You resign any officer or director positions at the Company and any subsidiaries of the Company, effective as of the Termination Date.
3.    Business Records and Your Continuing Obligations. You represent that You have returned to the Company any and all property belonging to the Company, including but not limited to business records and documents relating to any activity of the Company or its Affiliates, files, records, documents, plans, drawings, specifications, equipment, software, pictures, and videotapes, whether prepared by You or not and whether in written or electronic form.
4.    Confidentiality and Restrictive Covenant Agreements.
a.    You understand that You remain bound by the Confidentiality and Assignment of Invention Agreement and Restrictive Covenant Agreement signed by You on December 11, 2017, and any other confidentiality, non-competition or non-solicitation agreements You signed during Your employment with the Company, which remain in full force and effect pursuant to their terms. You agree that the consideration provided to You under this Agreement shall serve as additional consideration for the continuing requirements and restrictions contained in such agreements.
b.    You further understand and agree that the terms of this Agreement, and the circumstances and/or discussions leading to this Agreement, are confidential and that You will not disclose such terms or communicate the contents of this Agreement to any third-party, other than to Your immediate family members, attorneys, or accountants (provided that any such party to whom You disclose such information makes a promise, for the benefit of the Company, to keep such information confidential). Nothing in this Agreement shall preclude You from disclosing such information to any governmental taxing authorities or as otherwise required by law.
Note: Notwithstanding any other provision of this Agreement, or any other agreement, You will not be held criminally or civilly liable under any federal or state trade secret law for any disclosure of a trade secret that is made (1) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, solely for the purpose of reporting or investigating a suspected violation of law; or (2) in a complaint or other document that is filed under seal in a lawsuit or other proceeding. If You file a lawsuit for retaliation by the Company for reporting a suspected violation of law, You may disclose the Company’s trade secrets to Your attorney and use the trade secret information in a court proceeding so long as You (1) file any document containing the trade secret under seal and (2) do not disclose the trade secret, except pursuant to court order.
5.    Your Further Agreements and Acknowledgements. You further agree or acknowledge:
a.    You have carefully read and fully understand all of the provisions of this Agreement, which is written in a manner You clearly understand.
b.    You are entering into this Agreement knowingly, voluntarily, and with full knowledge of its significance, and have not been coerced, threatened, or intimidated into signing this Agreement.
c.    You received a copy of this Agreement to review on the Termination Date.

- 4 -


d.    You have 21 days from the Termination Date to consider whether to accept this Agreement (although You may sign it at any time prior to the expiration of such 21-day review period, if You wish, in Your sole discretion). You may accept this Agreement by signing and returning the signed copy so that it is received by the Company (c/o Mary L. Frontczak at the Company’s corporate headquarters located at 9900 W. 109th Street, Suite 100, Overland Park, Kansas 66210) via hand-delivery, certified mail, overnight express mail or e-mail (legal@compassminerals.com) within the 21-day period following receipt of this Agreement.
e.    that further revisions or changes to this Agreement, whether material or immaterial, do not restart the running of the 21-day review period.
f.    the Company advises You to consult with independent legal counsel regarding this Agreement.
g.    the Company advises You to consult with an independent financial advisor regarding the tax treatment of any payments or benefits under this Agreement.
h.    You may revoke this Agreement within 7 calendar days after You sign it by providing written revocation, during that time, to the Company (c/o Mary L. Frontczak at the Company’s corporate headquarters located at 9900 W. 109th Street, Suite 100, Overland Park, Kansas 66210) via hand-delivery, certified mail, overnight express mail or e-mail (legal@compassminerals.com) within the 7-day revocation period.
i.    this Agreement shall be effective and enforceable on the 8th calendar day following the date You execute it, provided You do not earlier revoke it (the “Effective Date”).
j.     the consideration the Company has provided in this Agreement exceeds anything to which You are entitled in connection with Your employment or Your departure from the Company, including under Section 4 of the Severance Plan. You agree that You are not entitled for any reason, or under any other agreement with the Company or its Affiliates, including the Severance Plan, to receive any consideration other than, or in addition to, that which You are receiving under this Agreement.
k.    neither the Company nor its Affiliates has made any representations or warranties to You regarding this Agreement, including the tax treatment of any payments or benefits under this Agreement, and neither the Company nor its Affiliates shall be liable for any taxes, interest, penalties, or other amounts owed by You.
l.    You hereby represent to the Company that You are not a Medicare beneficiary, and no conditional payments have been made by Medicare to or on behalf of You, as of the date You executed this Agreement. You agree to indemnify, defend, and hold harmless the Company and its Affiliates from any Medicare-related claims, including but not limited to any liens, conditional payments, rights to payment, multiple damages, or attorneys’ fees.

6.    The Parties’ Additional Agreements and Acknowledgments. The Parties further agree and acknowledge:

a.    neither the existence of this Agreement nor anything in this Agreement shall constitute an admission of any liability on the part of You, the Company, or any of the Company’s Affiliates, the existence of which liability the Parties expressly deny.


- 5 -


b.    except as provided herein, this Agreement contains the entire agreement between You and the Company with respect to the matters contemplated hereby, and no modification or waiver of any provision of this Agreement will be valid unless in writing and signed by You and the Company.
c.    this Agreement shall be construed in accordance with the laws of the State of Kansas, the federal and state courts of which shall have exclusive jurisdiction over all actions related to this Agreement.
d.    this Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which shall constitute together one and the same Agreement, and a signed copy of this Agreement delivered by facsimile, pdf, e-mail or other means of electronic transmission is deemed to have the same legal effect as delivery of an original.
e.    neither of the Parties is relying on any representation not contained herein; the Parties shall be considered joint authors in the event of any dispute concerning this Agreement, and no provision shall be interpreted against any of the Parties because of alleged authorship; this Agreement shall not be strictly construed by or against You, the Company, or any of the Company’s Affiliates; and the Parties’ intent is that this Agreement shall be interpreted as reasonable and so as to enforce the Parties’ intent and to preserve this Agreement’s purpose.
f.    this Agreement is binding on, and inures to the benefit of, the Company’s successors and assigns and Your heirs, agents, executors, successors and assigns.

g.    that the Company may assign this Agreement, including but not limited to Your releases and waivers, Your additional agreements or prohibitions, and any other confidentiality or restrictive covenant obligations or agreements signed by You, including those referenced in Section 4(a).

[The remainder of this page is intentionally blank]


- 6 -


SIGNATURE PAGE
I have fully and carefully read and considered this Agreement and acknowledge that I understand it. I am signing this Agreement voluntarily with full knowledge I am waiving my legal rights and that I will be bound by all agreements, representations, and acknowledgments set forth herein:


Date:
February 21, 2020
 
/s/ Angela Y. Jones
 
 
 
 
Angela Y. Jones
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COMPASS MINERALS INTERNATIONAL, INC.
 
 
 
 
 
Date:
2/24/2020
By:
/s/ Kevin Crutchfield
 
 
Name:
Kevin Crutchfield
 
 
 
Title:
CEO
 
 
 
 
 

- 7 -
Exhibit 10.2



Consulting Agreement

This Consulting Agreement (this “Agreement”) is entered into as of 21 February, 2020 (the “Effective Date”) by and between Angela Y. Jones (“Consultant”) and Compass Minerals International, Inc., a Delaware corporation (the “Company”) (collectively, the “Parties”).
WHEREAS, Consultant served as the Company’s Chief People Officer until February 19, 2020;
WHEREAS, contemporaneously herewith Consultant and the Company have agreed to that certain Final Release and Waiver of Claims (the “Release”);
WHEREAS, the Company desires to continue to benefit from the expertise and experience of Consultant following her termination of employment; and
WHEREAS, the Company desires to retain Consultant as a consultant of the Company, and Consultant desires to be so retained by the Company, on the terms and subject to the conditions more fully set forth in this Agreement.
Now, Therefore, in consideration of the mutual promises and conditions contained herein, the Parties agree as follows:
1.Consulting Services. In consideration for the Company’s agreement to the terms set forth in the Release, and provided Consultant timely signs, and does not revoke, the Release as provided therein, the Company agrees to retain Consultant effective as of the Effective Date to render such consulting and advisory services (the “Consulting Services”), as the Company may reasonably request from time to time, which Consulting Services shall include providing consultation with respect to human resources and related matters. Consultant shall provide the Consulting Services solely at the request of and pursuant to the direction of the Company’s Chief Executive Officer, Chief Financial Officer, Chief Legal Officer, head of Human Resources, any Vice President in the Company’s Human Resources function or any individual serving in similar functional roles (the “Designated Individuals”). The period in which Consultant shall be available to provide such Consulting Services shall begin on the Effective Date and end on the earlier of December 31, 2020 or the date the Consulting Services are terminated pursuant to this Agreement (the “Consulting Period”). The Consulting Services will require no more than fifteen (15) hours per week, and no more than forty (40) hours per month, of Consultant’s time. Consultant hereby accepts such engagement and agrees to perform such Consulting Services for the Company upon the terms and conditions set forth in this Agreement. Consultant shall perform the Consulting Services only at mutually agreeable times and at a mutually agreeable location, which such agreement shall not be unreasonably withheld. Consultant may accept engagements by or employment with one or more third parties during the Consulting Period, provided Consultant continues to provide the Consulting Services pursuant to the terms of this Agreement and honors all covenants set forth in this Agreement and the Parties’ Confidentiality and Assignment of Invention Agreement and Restrictive Covenant Agreement.

2.Compensation. As compensation for the Consulting Services to be rendered by Consultant and Consultant’s commitments hereunder, the Company shall pay Consultant the total fee of $250,000, payable in substantially equal installments each month of the Consulting Period (the “Monthly Consulting Fee”). The Company will report all compensation paid to Consultant under this Agreement on IRS Form 1099, to the extent required to do so under the Internal Revenue Code. All amounts paid to Consultant under this Agreement shall constitute income from self-employment, and Consultant will be solely responsible for paying any and all federal, state, and local taxes (including FUTA and FICA) on compensation received under this Agreement. Consultant will indemnify the Company for, and hold it harmless from, any and all liability arising from any failure to withhold or pay such taxes and/or Consultant’s tax treatment under this Agreement. Consultant must complete and submit a Form W-9 to the Company before any compensation under this Agreement will be issued. Upon the termination of the Consulting Period for any reason, all future payments pursuant to this Agreement will cease; provided, however, in the event the Consulting Period is terminated by the Company without Cause or by Consultant for Good Reason pursuant to Section 5, the Company’s obligation to pay the Monthly Consulting Fee as provided in this Section 2 shall continue through December 31, 2020. For the avoidance of doubt, if Consultant does not timely execute, or if Consultant revokes, the Release as provided therein, this Agreement shall be null and void, and the Company shall not be obligated to pay any Monthly Consulting Fees or any other remuneration to Consultant under this Agreement.




3.Expenses. Consultant shall be entitled to receive reimbursement for all reasonable expenses, including travel expenses, incurred by Consultant at the request of the Company in connection with the performance of the Consulting Services within thirty (30) calendar days following submission of evidence of such expense by Consultant to the Company in accordance with the policies, practices and procedures of the Company as applied to its executive officers.
 
4.Independent Contractor Status. Consultant and the Company intend and agree that Consultant shall perform the Consulting Services as an independent contractor and not as an employee of the Company. The manner of and means by which Consultant executes and performs her obligations hereunder are to be determined by Consultant in her reasonable discretion. Consultant is not authorized to and shall not assume or create any obligation or responsibility, express or implied, on behalf of, or in the name of the Company or to bind the Company in any manner. Consultant agrees that she will not describe or hold herself out as an employee or agent of the Company. Consultant shall not be entitled to participate in or receive any benefits under any Company programs maintained for its employees. Should Consultant be deemed to have any rights of participation in any such programs, by signing below, Consultant hereby waives such rights freely, knowingly, and voluntarily. Nothing in this Agreement creates any agency, joint venture, partnership or other form of joint enterprise, or fiduciary relationship between the Parties.

5.Termination of Consulting Arrangement. The consulting arrangement created by Section 2 of this Agreement between the Company and Consultant and the Consulting Period may be terminated only (a) by a mutual written agreement of the Company and Consultant, (b) by the Company for Cause (as defined below), or (c) by Consultant for Good Reason. “Good Reason” means the Company’s failure to pay within the fourteen (14) calendar day period following the date any Monthly Consulting Fee payment is due (as specified in Section 2), provided, that such failure is not cured within fourteen (14) calendar days of receipt by the Company of written notice of the failure to be provided by Consultant no earlier than the 11th day following the date such payment was originally due. “Cause” means (i) Consultant’s willful failure or refusal to perform in all material respects Consultant’s duties or to carry out in all material respects the reasonable and lawful directives of the Company or any Designated Individuals pursuant to this Agreement which remains uncorrected fourteen (14) calendar days after receipt of written notice of such failure or refusal, or (ii) any other material breach by Consultant of the terms of this Agreement after receipt of written notice of such breach that remains uncorrected fourteen (14) calendar days after Consultant receives written notice of such breach. For avoidance of doubt, Consultant’s refusal to perform Consulting Services that Consultant reasonably believes are unlawful or incriminating to Consultant shall not be deemed failure or refusal to perform.

6.Confidentiality and Non-Disparagement. The Parties agree that the confidentiality and non-disparagement clauses and all other covenants contained in the Release shall continue in full force and effect pursuant to their terms, both during and after the Consulting Period.

7.Notices. Any notice or other communication required or permitted hereunder shall be in writing and either personally delivered, sent by a reputable overnight carrier with signature required, or transmitted by email, addressed as follows:

 
If to Consultant:
 
If to the Company:
 
 
Angela Y. Jones    
 
Compass Minerals International, Inc.
 
 
(last known personal address and email)    
 
9900 West 109th Street, Suite 100
 
 
 
 
Overland Park, KS 66210
 
 
 
 
Attention: Chief Legal Officer
 
 
 
 
Email: legal@compassminerals.com
 

2



8.
Miscellaneous.

a.Entire Agreement. Together with the Release, the Confidentiality and Assignment of Invention Agreement, and the Restrictive Covenant Agreement, this Agreement constitutes the entire agreement of the Parties and there are no other promises or conditions in any other agreement whether oral or written. This Agreement supersedes and cancels any prior written or oral agreements between the Parties in respect of the subject matter of this Agreement.

b.Amendment. This Agreement may be modified or amended if the amendment is made in writing and is signed by authorized representatives of both Parties.

c.Severability. If any provision of this Agreement shall be held to be invalid or unenforceable for any reason, the remaining provisions shall continue to be valid and enforceable. If a court finds that any provision of this Agreement is invalid or unenforceable, but that by limiting such provision it would become valid and enforceable, then such provision shall be deemed to be written, construed, and enforced as so limited.

d.Waiver of Contractual Right. The failure of either Party to enforce any provision of this Agreement shall not be construed as a waiver or limitation of that Party's right to subsequently enforce and compel strict compliance with every provision of this Agreement.

e.Applicable Law. This Agreement shall be governed by the laws of the state of Kansas, without regard to principles of conflicts of laws. The Parties consent and submit to the exclusive jurisdiction of the federal and state courts of Johnson County, Kansas for any matters arising out of this Agreement or the relationship between them.

f.Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. In the event that any signature is delivered by electronic transmission, such signature page may serve as an original.

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first set forth above to be effective as of the Effective Date.
Company:
 
Consultant:
 
COMPASS MINERALS INTERNATIONAL, INC.
 
 
 
 
 
 
 
 
By:
/s/ Kevin Crutchfield
 
/s/ Angela Y. Jones
 
 
Kevin Crutchfield
 
By: Angela Y. Jones
 
 
President and CEO
 
 
 
 
 
 
 
 


    

3


Exhibit 31.1


CERTIFICATION

I, Kevin S. Crutchfield, certify that:
1.
I have reviewed this quarterly report on Form 10-Q of Compass Minerals International, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 6, 2020
By:
/s/ Kevin S. Crutchfield
 
 
 
Kevin S. Crutchfield
 
 
 
President and Chief Executive Officer
 
 
 





Exhibit 31.2


CERTIFICATION

I, James D. Standen, certify that:
1.
I have reviewed this quarterly report on Form 10-Q of Compass Minerals International, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 6, 2020
By:
/s/ James D. Standen
 
 
 
James D. Standen
 
 
 
Chief Financial Officer
 
 



Exhibit 32

CERTIFICATION PURSUANT TO 18 U.S.C. §1350

Each of the undersigned hereby certifies that this quarterly report on Form 10-Q for the period ended March 31, 2020, as filed with the Securities and Exchange Commission on the date hereof, based on my knowledge, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Compass Minerals International, Inc.

 
 
 
Date: May 6, 2020
By:
/s/ Kevin S. Crutchfield
 
 
Kevin S. Crutchfield
 
 
President and Chief Executive Officer
 
 
 
 
By:
/s/ James D. Standen
 
 
James D. Standen
 
 
Chief Financial Officer






Exhibit 95

Mine Safety Disclosure

We understand that to prevent employee and contractor injuries, we must approach safety excellence from many directions at once. We have developed a three-pronged approach towards world class safety performance. This approach consists of (1) setting a high standard of risk mitigation, (2) having robust safety management systems, and (3) supporting a culture of full engagement and personal accountability at all levels of the organization.

We continuously monitor our safety performance by assessing injury and non-injury incidents (e.g., near misses/near hits) as well as key performance indicators. We believe our approach to safety excellence will help us deliver on our commitment to our employees, contractors, their families and our customers to provide a safe working environment.

Mine Safety Data

A subsidiary of Compass Minerals International, Inc. owns and operates the Cote Blanche mine, an underground salt mine located in St. Mary Parish, Louisiana. The Cote Blanche mine is subject to regulation by the Mine Safety and Health Administration (“MSHA”) under the Federal Mine Safety and Health Act of 1977, as amended (the “Mine Act”).

MSHA is required to regularly inspect the Cote Blanche mine and issue a citation, or take other enforcement action, if an inspector or authorized representative believes that a violation of the Mine Act or MSHA’s standards or regulations has occurred. MSHA is required to propose a civil penalty for each alleged violation that it cites.

We have the option to contest any enforcement action or related penalty we receive before the Federal Mine Safety and Health Review Commission. As a result of this process, an enforcement action may be modified or vacated and any civil penalty proposed by MSHA for an alleged violation may be increased, reduced or eliminated. However, under the Mine Act, we are required to abate (or correct) each alleged violation within a specified time period, regardless of whether we contest the alleged violation.



The table below sets forth information for the reporting period ended March 31, 2020 concerning certain mine safety violations and other regulatory matters pursuant to requirements under the Dodd-Frank Wall Street Reform and Consumer Protection Act and Securities and Exchange Commission rules and regulations. The information only reflects our U.S. mining operations, as these requirements do not apply to mining operations outside the U.S.

Mine Name/
Mine I.D.
Number
Section 104 S&S Citations & Orders1
Section 104(b) Orders2
Section 104(d)
Citations & Orders3
Section 110(b)(2) Violations4
Section 107(a) Orders5
Total Dollar Value of MSHA Proposed Assessments
(Actual Amount)
Total Number of Mining Related Fatalities
Received Notice of Pattern of Violations under Section 104(e)
(Yes/No)6
Legal Actions Pending as of Last Day of Period
Legal Actions Initiated During Period
Legal Actions Resolved During Period
Cote Blanche Mine/16-00358
6
0
2
0
0
$12,824
0
No
0

0
0












1
Represents the number of citations and orders issued under section 104 of the Mine Act for alleged violations of mandatory health or safety standards that could significantly and substantially contribute to a mine health and safety hazard. The number reported includes no orders alleging an S&S violation issued under Section 104(g) of the Mine Act.
2
Represents the number of orders issued under section 104(b) of the Mine Act for alleged failures to abate a citation issued under section 104(a) of the Mine Act within the time period specified in the citation.
3
Represents the number of citations and orders issued under section 104(d) of the Mine Act for alleged unwarrantable failures (aggravated conduct constituting more than ordinary negligence) to comply with mandatory safety or health standards.
4
Represents the number of violations issued under section 110(b)(2) of the Mine Act for alleged “flagrant” failures (reckless or repeated failures) to make reasonable efforts to eliminate a known violation of a mandatory safety or health standard that substantially proximately caused, or reasonably could have been expected to cause, death or serious bodily injury.
5
Represents the number of orders issued under section 107(a) of the Mine Act for alleged conditions or practices which could reasonably be expected to cause death or serious physical harm before the condition or practice can be abated.
6
Section 104(e) written notices are issued for an alleged pattern of violating mandatory health or safety standards that could significantly and substantially contribute to a mine safety or health hazard.

2